The Journal of Pain

Headache related alterations of visual processing in migraine patients. --Manuscript Draft--

Manuscript Number:	JPAIN-D-19-00632R1
Article Type:	Human Study
Section/Category:	Observational Study *
Keywords:	Visual evoked potentials, spectral analysis, episodic migraine, chronic migraine, feedback, feedforward.
Corresponding Author:	Jean Schoenen, MD, PhD BELGIUM
First Author:	Marco Lisicki
Order of Authors:	Marco Lisicki
	Kevin D'Ostilio, PhD
	Gianluca Coppola, MD, PhD
	Romain Nonis, BSc
	Alain Maertens de Noordhout, MD, PhD
	Vincenzo Parisi, MD
	Delphine Magis, MD, PhD
	Jean Schoenen, MD, PhD
Abstract:	Migraine is characterized by an increased sensitivity to visual stimuli that worsens during attacks. Recent evidence has shown that feedforward volleys carrying incoming visual information induce high frequency (gamma) oscillations in the visual cortex, while feedback volleys arriving from higher order brain areas induce oscillatory activity at lower frequencies (theta/alpha/low-beta). We investigated visually induced high (feedforward) and low (feedback) frequency activations in healthy subjects and various migraine patients. Visual evoked potentials from 20 healthy controls and 70 migraine patients (30 inter-ictal and 20 ictal episodic migraineurs, 20 chronic migraineurs) were analysed in the frequency domain. We compared power in the theta-alpha-low beta and gamma range between groups, and searched for correlations between the low-to-high frequency activity ratio and number of monthly headache and migraine days. Compared to healthy controls, inter-ictal migraine patients had increased visually induced low frequency (feedback) activity. Conversely, ictal and chronic migraine patients showed an augmented gamma band (feedforward) power. The low-frequency-to-gamma (feedback/feedforward) activity ratio correlated negatively with monthly headache days and tended to do so with migraine days. Our findings show that visual processing is differentially altered depending on migraine cycle and type. Feedback control from higher order cortical areas predominates interictally in episodic migraine while migraine attacks and chronic migraine are associated with enhanced incoming afferent activity, confirming their similar electrophysiological profile. The presence of headache is associated with proportionally higher gamma (feedforward) activities.

Data Statement

Click here to access/download **Data Statement** Cover Letter.docx

Reviewers' comments:

Reviewer #2:

The authors present a manuscript exploring differential visual processing in healthy controls, migraine (ictal v's inter-ictal), and chronic migraine patients. They demonstrate that during the ictal phase and in chronic migraine patients there was an alteration in the gamma band (feedforward) as oppose to low frequency alterations in the inter-ictal patients compared to healthy controls. The results add an interesting dimension to the current body of literature on visual processing abnormalities in migraine and I only have minor comments.

1. Why were the same patients not recorded for the ictal v's inter-ictal phases as this would have made the findings more robust. While it is accepted and highlighted as a limitation the rationale for not doing it is not clear.

In agreement with the referee's comment, we acknowledge in the discussion that recording the same patients both during and outside of an attack would have made our findings more robust and should be planned in future studies (limitations on page 10/ line 18-20). This, however, is logistically more demanding for the patient and the investigator, as 2 recording sessions are necessary in each subject and the migraine attack is not programmable. We chose therefore, like in several other studies.^{1,2}, to perform most ictal recordings in patients who consulted our headache clinic during an ongoing migraine attack.

1. Chen WT, Wang SJ, Fuh JL, et al. Persistent ictal-like visual cortical excitability in chronic migraine. Pain 2011; 152: 254–258.

2. Coppola G, lacovelli E, Bracaglia M, et al. Electrophysiological correlates of episodic migraine chronification: evidence for thalamic involvement. J Headache Pain 2013; 14: 76.

2. This reviewer does not agree that the results support that chronic migraine is a "never-ending migraine attack", in fact the results show that abnormalities correlate better with headache (not migraine) frequency and ultimately given the high frequency of attacks in CM patients would always be in the 72 hour attack free zone used to define inter-ictal phase and as such this bold statement, while likely correct is not substantiated.

We agree with the reviewer that reporting that our results support the concept that chronic migraine is like a "never-ending migraine attack" may be an overstatement. We have therefore made it clear in the abstract, main body and discussion that the similarity between ictal recordings in episodic migraine and chronic migraine is only for the electrophysiological profile with proportionally increased gamma band activity (feedforward). As pointed out by the referee, we have now underscored that headache (not necessarily migraine headache) is associated with this profile and that in chronic migraine most recordings are more likely to occur within 72h of a headache. We have also mentioned (page 9 / lines 23 - 30) that the similar electrophysiological profile of a qualified migraine attack and a tension-type like headache in migraineurs favours the concept that both headache types have the same pathophysiological underpinning.

3. ICHD3 is no longer a beta version an is available in full, cite the updated version.

We know that the ICHD-3 is now available in its final version. However, at the time our study was conducted it was not, and we used the beta version to diagnose and select patients.

4. Did the authors attempt to see if photophobia impacted on the results, given this data was collected in the diary?

The headache diaries we used for this study, which are routinely used in our headache clinic, are intended to be diagnostic and follow-up tools based on the ICHD criteria. They therefore only question about presence or absence of photophobia and phonophobia during a headache. Unfortunately, they do not allow a more detailed analysis of photophobia, which would have been an added value for the study. We have now mentioned this in the "limitations" section of the manuscript (page 10 / lines 26 -27).

5. Where a non-normally distributed result was being further studied for correlation should the Spearmans coefficient have been used?

We have now performed more adequate, non-parametric, Spearman's test suggested by the reviewer. . The manuscript has been modified accordingly in the "methods" and "results" sections. Figure 3 has also been corrected.

6. In areas the P value is noted with either a comma or a decimal point. Please update all to decimal points.

P values are now all shown with decimal points.

7. Figure 5 is of limited value as is and could be turned into a more graphical abstract representation of the results that would be better received.

Thank you for your suggestion. Figure 5 has now been modified in an attempt to provide a more graphical explanatory scheme of the results.

Reviewer #3:

Overall the study is well designed and well presented. The strength of the manuscript is the comparisons between episodic migraine patients during and between attacks, chronic migraine patients and healthy controls.

The association of gamma activity to pain may already be known to the literature, however the potential suppressive role of low-frequency (feedback) activity on the pain related gamma activity and the association of the ration to migraine and headache attacks are

interesting.

Major concerns:

1) The authors will need to explain more the following conclusion: "Our findings support the notion that from an electrophysiological perspective chronic migraine can be conceptualized as a 'never-ending migraine attack'."

It appears that between attacks there is an increase in the lowfrequency activity but there is no increase in gamma activity. The attacks and chronic migraine conditions are characterized by increase in gamma activity. Do the authors mean that the ongoing Gamma activity is suppressed by the low frequency activity and therefore it is not increase between attacks?

As mentioned above, we agree that reporting that our results support the concept that chronic migraine is like a "never-ending migraine attack" may be an overstatement. We have therefore made it clear in the abstract, main body and discussion that the similarity between ictal recordings in episodic migraine and chronic migraine is only for the electrophysiological profile with proportionally increased gamma band activity (feedforward). As suggested by the reviewer and mentioned in the text, the feedback inhibitory drive may well suppress between attacks the feedforward gamma activity in a homeostatic perspective (page 9 / lines 4 - 14). This however would be overtaken by an increased gamma drive during a headache both during an attack in episodic migraine but permanently in chronic migraine, which may favour a rupture of metabolic homeostasis. Hence the notion that chronic migraine is similar to a migraine attack from an electrophysiological point of view. We have now underscored that headache (not necessarily migraine headache) is associated with this profile and that in chronic migraine most recordings are more likely to occur within 72h of a headache. We have also mentioned (page 9 / lines 23 – 30) that the similar electrophysiological profile of a qualified migraine attack and a tension-type like headache in migraineurs favours the concept that both headache types have the same pathophysiological underpinning.

2) The low-frequency activity level may be affected by the time elapsed since the last migraine attack. It would be helpful if the authors shown this association and correlation between the activity and time since last painful headache episode

We agree with the referee that the cyclic nature of migraine reflects in cerebral electrophysiological responses and we have confirmed this in our previously published studies. This is the reason why interictal recordings are performed at an interval of at least 72h after the last and before the next attack, as mentioned in the "methods" section. The most prominent electrophysiological changes occur periictally within this time window. We have therefore not paid attention in this study to changes that might occur at longer time intervals. As mentioned by the reviewer, such (subtle) changes might nonetheless occur and reflect slow fluctuations in thalamo-cortical rhythms. Capturing them needs ideally a longitudinal study with multiple recordings in the same patients, which is certainly of great interest for future studies This has been added to the "limitations" section of the manuscript (page10 / lines 20 - 23).

Minor concerns:

1) "The low-frequency-to-gamma (feedback/ feedforward) activity ratio correlated more strongly with total monthly headache days than with

migraine specific days" Please explain what non-specific headache episodes were included in this analysis.

Only headaches fulfilling the diagnostic criteria for a migraine attack (ICHD-3 beta code 1.1) (unless they had been treated with a triptan) were considered migraine specific headaches. All other episodes of head pain were coded as unspecific headaches. This is clarified on page 5.

2) "three of the ictal group had it not more than 48 hours before the test"

Were those patients results in line with the patients that had the recording during the attack?

Yes; the averaged low-frequency-to-gamma activity ratio in this small subset of patients is the same as that of the whole ictal group (0.67).

3) "Participants did not take any medication on a daily basis and, at the time of recordings, migraine patients had not taken any preventive anti-migraine treatment for at least 3 months." Medication taking status is not clear: Did the patients take any other medication during the attack / chronic pain such as triptans or NSAIDs ? If some of them did, were the results different from those that did not take medications.

Patients were not under any preventive treatment, nor had they been for the 3 preceding months. For the sake of clarity, this has been corrected in the manuscript on page 5 lines 8 - 9.

Were the patients instructed not to take medications during the migrainous attack?

For ethical reasons, patients were not instructed not to take medications during the attack. However, recordings are not possible in patients with very severe attacks, and hence, the intensity of attacks was most often moderate at the time of the recordings, explaining why, with rare exceptions, patients withheld acute therapy until the end of recordings.

Reviewer #4:

Migraine headaches are associated with various visual phenomenon that are poorly understood but strongly associated for diagnosis and consequently treatment. This study "Headache related alterations of visual processing in migraine patients" is targeted in this important but relatively less understood area of headaches. The manuscript is well written. The tables and figures are appropriate and help assimilate data easily. The study certainly poses interesting questions and attempts to uncover fundamental neurophysiological underpinnings using EEG and VEP.

Major comments:

1. A. In page 5, Line 20, authors say "The investigators in this study were not blinded to the diagnosis, but all electrophysiological analyses were full automated." Is there a reason why investigators could not be blinded. I would ask them to include 1-2 lines why they decided to unblind the investigators.

The reason for not blinding the investigators in this study is explained by the available human resources: the researchers in charge of data collection also had to analyse the data. This limitation was partially overcome by performing automated analyses. Nonetheless we agree with the referee that a blinded protocol would have been advantageous. We have now included a statement concerning this limitation on page 10 / lines 16 – 17 of the revised version.

B. In discussion, the last paragraph about limitations, I would request the authors to included that the study not being blinded is a limitation.

We have now included a statement concerning this limitation 10 / lines 16 – 17 of the revised version.

2. In page 5, Line 1 the authors mention "Epochs whose amplitude exceeded a two standard deviations from the channel mean amplitude limit were considered artefacted and rejected (<6% of epochs). In EEG analysis, 2 standard deviations above the baseline on power spectral analysis is considered seizure in epilepsy EEG literature.

A. Is that established parameter in EEG analysis for headaches that 2 standard deviations from channel mean is an artifact ? Please include source/reference for that established precedent.

The selected threshold is not headache specific, and was empirically chosen in order to separate artefacted from non-artefacted epochs on the basis of the law of normal distribution. We presupposed that bad epochs (e.g. blink artefacts, movement...) would behave as outliers in terms of amplitude. This threshold has been useful for us in previous studies but, as the referee correctly points out, it needs to be specifically tested as a suitable parameter. As mentioned below, this has now been added to the revised version of the manuscript.

B. If not, please include in discussion as a limitation of the study.

We have now included the artefact rejection method as a limitation of our study on page 10 / lines 9 - 12.

Minor comments:

1. Table 1, the authors use commas (,) instead of (.) for p-values. Please correct.

Thank you for this observation. This error has been corrected in the revised version.

2. Table 2, the authors again use commas (,) for every value in the table. Is that accurate ?

Thank you for this observation. This error has been corrected in the revised version.

Reviewer #5:

Aim of this study was to investigate low (feedback) and high (feedforward) frequency visually induced activations in healthy subjects and migraine patients during the ictal and inter-ictal periods.

Visual evoked potentials from 90 participants (30 inter-ictal and 20 ictal episodic migraine patients, 20 chronic migraine patients and 20 healthy controls) were analysed in the frequency domain. Power in the theta-alpha-low beta (feedback) and gamma (feedforward) peaks was compared between groups. In addition, correlations between the feedback/feedforward activity ratio and number of monthly headache attacks were examined.

The findings support the notion that from an electrophysiological perspective chronic migraine can be conceptualized as a 'never-ending migraine attack'. All headaches, and not only those with typical migraine features, were associated to alterations in cortical visual processing.

The issue is surely of great interest and the study is well organised and written and provides an incremental increase in knowledge relatively to its purpose.

The only objection that could be raised is the fact - mentioned by the authors themselves- that different patients were included in the ictal and interictal episodic migraine groups while it would have being preferable to compare the same patients in and outside of an attack.

In agreement with the referee's observation, we acknowledge in the manuscript that recording the same group of patients during both the ictal and inter-ictal periods would have made our findings more robust and should be performed in future studies (limitations on page 10/ line 18-20Due to logistic constraints, we conducted this experiment under a design that resulted more feasible for us, in a similar way to that of prior studies.^{1,2} (see comment to referee 1).

2. Coppola G, lacovelli E, Bracaglia M, et al. Electrophysiological correlates of episodic migraine chronification: evidence for thalamic involvement. J Headache Pain 2013; 14: 76.

^{1.} Chen WT, Wang SJ, Fuh JL, et al. Persistent ictal-like visual cortical excitability in chronic migraine. Pain 2011; 152: 254–258.

Headache related alterations of visual processing in migraine patients.

Marco Lisicki^{1†}, Kevin D'Ostilio^{1†}, Gianluca Coppola², Romain Nonis¹, Alain Maertens de Noordhout¹, Vincenzo Parisi², Delphine Magis^{1#}, Jean Schoenen^{1#}*.

¹ Headache Research Unit, CHR Citadelle Hospital, CHU de Liège. University of Liège Belgium.

² IRCCS - Fondazione Bietti, Research Unit of Neurophysiology of Vision and Neurophthalmology, Rome, Italy

[†]These authors equally participated in this study. [#]These authors contributed equally to the supervision of the study.

*Corresponding Author

Prof Jean Schoenen: University of Liège. University Department of Neurology, CHR Citadelle Hospital, Boulevard du 12eme de Ligne 1, 4000 Liege, Belgium. jschoenen@uliege.be, +32/4/225.63.83.

Running title:

Feedback & feedforward visual activity in migraine

Disclosures:

Funding

This project was part of the EUROHEADPAIN project - FP7 n° 602633 and received support from the Fonds d'Investissements de Recherche Scientifique (FIRS) of the CHU de Liège. GC was supported by the G.B. Bietti Foundation and the Italian Ministry of Health and Fondazione Roma.

Conflict of Interest

The authors of this study have no relevant conflict of interest to declare.

1 Abstract:

Migraine is characterized by an increased sensitivity to visual stimulus-stimuli that worsens
during the attacks. Recent evidence has shown that while feedforward volleys carrying
incoming visual information induce high frequency (gamma) oscillations in the visual cortex,
while feedback volleys arriving from higher order brain areas induce oscillatory activity at
lower frequencies (theta/alpha/low-beta).

7 We investigated -visually induced high (feedforward) and low (feedback) and high 8 (feedforward) frequency visually induced activations in in healthy subjects and various 9 migraine patients during the ictal and inter-ictal periods. Visual evoked potentials from 20 healthy controls and 90-70 participants-migraine patients (30 inter-ictal and 20 ictal episodic 10 migraineurs-patients, 20 chronic migraineurs-patients and 20 healthy controls) were analysed 11 in the frequency domain. We compared pPower in the theta-alpha-low beta (feedback) and 12 gamma (feedforward) peaksrange was compared between groups, and . Insearched 13 addition; for correlations between the low-to-high frequency feedback/feedforward-activity 14 ratio and number of monthly headache headache and migraine daysattacks were examined. 15

16 Compared to healthy controls, inter-ictal migraine patients had an-increased visually induced 17 low frequency (feedback) activity. Conversely, ictal and chronic migraine patients showed an 18 augmented gamma band (feedforward) power. The low-frequency-to-gamma (feedback/ 19 feedforward) activity ratio correlated more stronglynegatively with total-monthly headache 20 days and tended to do so than with migraine specific days.

Our findings show that visual processing is differentially altered depending on migraine cycle 21 and type. Feedback control from higher order cortical areas predominates interictally in 22 episodic migraine while migraine attacks and chronic migraine are associated with enhanced 23 24 incoming afferent activity, confirming their similar electrophysiological profile. The presence of headache is associated with proportionally higher gamma (feedforward) activities. support 25 the notion that from an electrophysiological perspective chronic migraine can be 26 conceptualized as a 'never ending migraine attack'. All headaches, and not only those with 27 typical migraine features, are associated to alterations in cortical visual processing. 28

29 **Perspective:**

This study provides an insight into the pathophysiology of migraine headache froorm the perspective of cortical sensory processing dynamics. Patients with migraine present alterations in feedback and feedforward visual signalling that differ between the with the
 presence of headache and headache free periods...

3 Keywords:

- 4 Visual evoked potentials, spectral analysis, episodic migraine, chronic migraine, feedback,
- 5 feedforward.

1 Introduction

It is well established in healthy humans that marked changes in brain rhythmic oscillatory activity over a wide range of frequency bands are related to pain processing.^{30,32} This also applies for head pain associated to migraine. Several electrophysiological studies have shown that migraine is a brain disorder characterized by an abnormal cortico-subcortical oscillatory activity that fluctuates along the migraine cycle, differs between the ictal and inter-ictal intervals,^{7,12,34,35,46} and remains persistently altered as the disease chronifies.⁸

8 According to available experimental evidence, oscillations in the alpha and gamma frequency 9 bands can be used as direct, objective, experimentally stable, and interrelated measures of cognitive and sensory brain tasks. During on-going pain alpha power is reduced and gamma 10 power is increased in several brain regions,^{17,18,45} including posterior cortical areas.^{4,5} Similar 11 12 modifications correlate with active selection and integration of relevant unattended visual information, resulting from the balance between feedforward volleys reaching the visual 13 cortex from the lateral geniculate nucleus (fast gamma oscillations) and feedback activity 14 incoming from higher order visual areas (low frequency (theta/alpha/low-beta) 15 oscillations).^{24,28} Spectral analysis allows to easily identify these two main frequency peaks 16 (theta/alpha/low-beta and gamma) in common scalp-recorded visual evoked potentials 17 (VEPs), as confirmed by recent intracortical recordings in non-human primates as well as 18 magnetoencephalographic studies in humans.^{24,28} 19

In this study we analysed the previously described fluctuations of visual processing in migraine^{23,39} from the perspective of visually induced feedback (theta/alpha/low-beta) and feedforward (gamma) activations. We also tested whether these alterations in visual signalling were specifically associated to-with the number-frequency of full-blown migraine attacks, or if they were as wellalso related to recurrent episodesthe presence of mild tension-type like headaches, –often present in migraineurs, particularly in those suffering from ,—chronic migraine.

27

28 Subjects and methods

29 Subjects

The study involved 90 participants: 20 healthy volunteers (HV), 30 episodic migraine without aura patients recorded during a headache-free interval (minimum 72 hours before or after an

attack) verified on a headache diary and/or by a telephone call (EM), 20 ictal episodic 1 migraineurs recorded during an attack (IM, 17 during the headache phase, 3 within 48 hours 2 of the headache), and 20 chronic migraine patients without medication overuse (CM). 3 Diagnoses were made in accordance with The International Classification of Headache 4 Disorders 3rd edition beta version (ICHD3 beta).²⁰ Healthy volunteers did not report any first 5 degree relative suffering from recurrent headaches of any type. Participants were 6 7 consecutively recruited amongst University students or their families and via our headache clinic. Specifically, an announcement was posted in the University's intra-net, and headache 8 9 patients attending the consultation were personally invited to take part. Patients were not 10 under any preventive treatment, nor had they been for the 3 preceding months. Participants did not take any medication on a daily basis and, at the time of recordings, migraine patients 11 had not taken any preventive anti-migraine treatment for at least 3 months. To ascertain the 12 13 diagnosis, attack occurrence, and headache attacks severity, patients filled in a paper diary for \geq 30 days in which headache intensity, associated symptoms (nausea, vomiting, photo-, 14 phonophobia) and acute medication intake were registered. As in recent therapeutic trials,⁴¹ 15 only headaches fulfilling the diagnostic criteria for a migraine attack (ICHD3 beta code 1.1) 16 17 (unless they had been treated with a triptan) were considered migraine specific headaches. All other episodes of head pain were coded as unspecific headaches. None of the participants that 18 initially agreed to participate were excluded afterwards. The study was approved by the 19 20 Hospital's ethics committee (Centre Hospitalier Régional de la Citadelle, Liège, Belgium – protocol n°1422) and conducted following the principles of the Declaration of Helsinki. All 21 22 participants gave written informed consent.

23 Visual Evoked Potentials (VEP) recordings and analysis

24 VEP recordings were performed in the electrophysiology laboratory of the Headache Research Unit (Neurology Department, Centre Hospitalier Régional de la Citadelle, Liège, 25 26 Belgium). All participants were studied in the morning, between 9 a.m. and noon. Subjects were sitting on a comfortable armchair, in a quiet room with dimmed light. A patch was 27 28 placed over the left eye, and needle recording electrodes were introduced in the scalp at Oz (active) and Fz (reference) based on the 10-20 EEG system. During the recordings, subjects 29 30 were instructed to maintain fixation on a red dot in the centre of a screen which displayed a 31 black and white reversing checkerboard pattern (contrast of 80%, mean luminance 50 cd/m2). 32 Temporal and spatial stimulating frequencies employed were 1.55 Hz (3.1 reversals/second) and 68' respectively. Six hundred epochs, each lasting 250ms, were continuously recorded at 33

a sampling rate of 5.000 Hz using a CEDTM power 1401 device (Cambridge Electronic 1 Design Ltd, Cambridge, UK). After DC subtraction, recordings were exported to EEGLAB,¹³ 2 an open-source MATLAB (The MathWorks Inc.) toolbox for electrophysiological signal 3 processing, where they were band-pass filtered (low pass 100 Hz, high pass 1 Hz). Epochs 4 whose amplitude exceeded a two standard deviations from the channel mean amplitude limit 5 were considered artefacted and rejected (<6% of epochs). The Fast Fourier Transform was 6 7 applied on each epoch to compute spectral decomposition. Log-transform of single-trial spectral power was performed before averaging. Data were zero-padded in order to increase 8 frequency resolution to steps of 1Hz. As in previous studies,²⁸ the two most prominent peaks 9 of the spectrogram were observed in the theta/alpha/low-beta (1) and gamma (2) frequency 10 band ranges. To estimate power at these frequencies, the area under the curve (trapezoidal 11 12 numerical integration; MATLAB function 'trapz') of activity at each peak and nearby 13 surrounding frequencies (4 to 16 Hz for theta-alpha-low beta and 40 to 60 Hz for gamma) was calculated for each individual (Fig 1). Considering the recent evidence showing that alpha-14 15 beta and gamma activity embedded in visually-induced cortical responses convey different information,^{24,28} and that abnormal visual responsiveness in migraine is the result of a 16 complex process involving several cortical areas,²⁷ we calculated the low frequency-to-17 gamma activity ratio as a measure of the interaction between simultaneous volleys reaching 18 the visual cortex. In addition, considering the overlap between visually induced cerebral 19 20 gamma activity and the frequency spectrum of different possible sources of contamination of the signal (muscular artefacts, AC line noise) we performed a supplementary analysis of event 21 related spectral perturbations which permits to visually inspect changes in the power spectrum 22 throughout time. Investigators in this study were not blinded to diagnosis, but all 23 electrophysiological analyses were fully automated. 24

25 Statistical analysis

26 Statistical analyses and graphs were performed in Prism version 6.00 for Windows (GraphPad Software, La Jolla, California, USA). The assumption of normal distribution was assessed 27 28 using the Shapiro-Wilk normality test. Continuous variables were compared using ANOVA or Kruskal-Wallis tests (in case of non-normal distributions or violations in the assumption of 29 30 homoscedasticity evaluated using Bartlett's test), followed by post-hoc comparisons between 31 groups (corrected for multiple comparisons using Dunn's multiple comparison test). 32 Correlation analyses between spectral power ratios and monthly number of headache or migraine days were performed using Spearman's rank correlation test corrected for multiple 33

comparisons by applying a Bonferroni correction. Because alterations in the power spectrum
 of patients from the ictal migraine group are likely to be transient,^{1,39} these patients were not
 included in correlation analyses. The significance level for all tests was set at p<0.05.

4

5 **Results**

6 There were no significant between-group differences in mean ages or gender ratio in the
7 whole subject sample, nor between disease duration amongst migraine sub-groups (Table 1).

8 The results of spectral analyses are displayed in table 2. Mean low-frequency (theta-alpha-low 9 beta) power was significantly higher in headache-free episodic migraine patients compared to healthy controls (Kruskal-Wallis test H= 8.330, p=0.040; Dunn's multiple comparisons test 10 (episodic migraine patients vs healthy controls) p = 0.030, adjusted for multiple comparisons). 11 12 Conversely, gamma power was higher in both ictal and chronic migraine patients (Kruskal-Wallis test H= 14.00, p< 0.003; Dunn's multiple comparisons tests: chronic migraine vs 13 14 healthy controls, p=0.023; ictal migraine vs healthy controls, p=0.013, both adjusted for multiple comparisons) (Fig 1 & 2). The low-frequency-to-gamma activity ratio was 15 significantly smaller in ictal and chronic migraine patients compared to headache-free 16 episodic migraine patients, and in ictal migraine patients compared to healthy controls 17 (Kruskal-Wallis test H= $16_{\overline{1}}.33$, p= $0_{\overline{1}}.001$); Dunn's multiple comparisons tests: episodic vs 18 chronic, $p = 0_{\overline{1}}032$; episodic vs ictal, $p = 0_{\overline{1}}012$; healthy volunteers vs ictal, $p = 0_{\overline{1}}024$ (all 19 adjusted for multiple comparisons). A similar trend was observed between chronic migraine 20 patients and healthy controls, but it did not reach statistical significance (p=0.055)- (Fig 2). 21 22 The low-frequency-to-gamma activity ratio was negatively correlated with the total number of 23 monthly headache days ($p_{f}=-0.3734$; p=0.009015) and), but not with the total number of migraine specific days ($p_{\rm F}$ = -0.2925; p=0.04208) days, although the latter correlation did not 24 withstand correction for multiple comparisons (Fig 3). A partial correlation (controlling for 25 age) between the low-frequency / gamma activity ratio and the monthly headache days was 26 also significant (r= -.33; p= 0.02). The N1-P1 amplitude of the broad-band VEP $\frac{did}{was}$ not 27 significantly different significantly between the groups (healthy controls: $5.088\mu V \pm 1,444$; 28 headache free migraine patients: 5.860 μ V \pm 2.361; chronic migraine patients: 5.368 μ V \pm 29 2.281; ictal migraine patients: 6.396 $\mu V \pm 2.436$; (one-way ANOVA $F_{(3,86)} = 1_{\overline{2},2}399$; 30 p=0₇.249). Supplementary event-event-related spectral perturbations analysis (Fig 4) showed 31 that gamma activity exhibited temporal fluctuations, as one would expect from a neural 32

signal, rather than being constant over time, (as would be 50Hz power line noise or other
possible sources of signal contamination).

3 **Discussion**

We measured power of low (theta/alpha/low-beta) and high (gamma) frequency oscillations 4 embedded in pattern-reversal visual evoked potentials (PR-VEP) in healthy controls, episodic 5 migraine patients (both headache free and during or in between an-attacks), and chronic 6 7 migraineurs. The results show that, during headache, gamma power patients have is an increased greater in patients gamma power compared to than in healthy subjects. In-By 8 9 contrast, in the absence of headache, episodic migraine patients exhibit anhave increased power at low frequencyies power (theta/alpha/low-beta). Concordantly, the low-frequency-to-10 gamma activity ratio was significantly higher in headache--free patients compared to patients 11 12 experiencingthan during a migraine attack or in chronic migraineurs. and Furthermore, this ratio was negatively correlated with the monthly number of headache days. 13

14 We have previously found a decreased habituation of late visual induced gamma components studied visual induced gamma activity in headache-free interictal episodic migraine patients 15 and mainly found a decreased habituation of late gamma components.⁷ In the present study 16 we focused on total gamma power and its relation with the low-frequency power spectrum 17 18 analysed from ain the frequency-domain perspective, which is better suited to evaluate high frequency oscillations. There is strong evidence showing that , in the visual pathway, 19 feedforward (afferent) volleys incoming from the lateral geniculate nucleus induce 20 oscillations within the gamma frequency range in the primary visual cortex (Fig. 45). This 21 22 frequency range has been associated with the efficiency of stimulus processing by thalamocortical networks ^{15,36,40} and with the translation of the stimulus features into coherent 23 perception (for a review, see Gray and Singer, 1995⁴²; Tallon-Baudry and Bertrand, 1999⁴⁴). 24 Therefore, increased visually induced gamma (feedforward) activity during migraine attacks 25 and in chronic migraine may reflect augmented efficiency within the thalamo-cortical circuit. 26 This is in line with previous electrophysiological,^{8,9,23,43} and functional neuroimaging¹¹ 27 28 studies supporting showing that thalamo-cortical network activity is decreased in migraineurs during the headache-free interval, but increaseds during an migraine attack and with migraine 29 chronification. 30

On the other hand, it is known that pain is accompanied by widespread enhancement of gamma activity in the brain (prefrontal, mid-cingulate, and primary somatosensory cortices and insula)¹⁹ associated to-<u>with</u> contralateral alpha power reductions,³² which suggests that the former reflects tonic pain processing while the latter may be related to a top-down cognitive process linked to attention.^{4,5,17,18,45} Reciprocal anatomical and functional connections between the visual and the trigeminal systems are well documented in animals and human beings.^{3,25,31,37} In particular, convergence of nociceptive trigeminal and visual afferents in the posterior thalamus³⁰ may explain how head pain can amplify visually induced thalamocortical activity, and thus gamma power in PR-VEP.

8 By contrast, As opposed to feedforward afferent activity that generates gamma oscillations in the primary visual cortex, feedback volleys from higher order visual areas (V2-V4) induce 9 oscillatory activity in the primary visual cortex within the theta/alpha/low-beta frequency 10 range (Fig. 5) which that notably plays a role e, for instance, ion focusing attention to salient 11 unattended stimuli.^{24,28} Such Evidence shows that feedback volleys reaching the visual cortex 12 are capable of able to modulate ing the response to feedforward-visual afferents .^{14,21,23} Indeed. 13 low-frequency (feedback) activity is thought to by exert a selectively inhibiting inhibitory 14 effect on high frequency (gamma), feedforward) -oscillations, and thus to exert suggesting a 15 possible 'gating' role of the formerprocess.²² The sensory processing profile of migraine 16 patients makes them vulnerable to sensory overload,^{2,16} and therefore, in need of 17 compensatory protective mechanisms. Between attacks, repetitive photic stimulation causes 18 whole-brain alpha hyper-synchronization,⁴⁶ indicative of a diffuse cortical deactivation,³³ 19 which may be favoured by the lower interictal activity in thalamocortical networks.⁸ Our 20 finding of increased theta/alpha/low-beta power during the interictal phase of episodic 21 migraine may thus reflect an increased feedback inhibition restraining thalamo-cortical 22 23 feedforward afferents as a protective (or compensatory) mechanism. 24 AccordinglyConcordantly, short-range lateral inhibition in the visual cortex of episodic migraineurs was found to be initially increased at the beginning of a sustained visual 25 stimulation protocol, but subsequently decreased as with subsequent persistent stimulus 26 presentation-persisted.¹⁰ This phenomenon likely contributes to the lack of habituation of 27 common broad-band pattern-reversal visual evoked potentialsPR-VEP, and underscores 28 supports the possibility hypothesis that its the protective mechanism against sensory overload 29 30 in migraine patients may at some point become overwhelmedovertaken.

The <u>ratio between low_-frequency and -to-gamma power was negatively correlated with</u>
 disease activity, but more so with headache days than with qualified migraine days. activity
 ratio that we used to measure the relation between feedback and feedforward activity in this

study showed marked disparities between the groups. Its relative lower value in reduction 1 observed in chronic migraineurs migraineurs could be due to the higher frequency of 2 headache days in these patients rendering them and to the fact that patients with frequent 3 4 headaches are more likely to be recorded in close temporal relation to an attack. Interestingly, 5 this ratio was remarkably similar between ietal episodic migraine patients and chronic migraineurs; a resemblance that has been described for other electrophysiological features in 6 7 the past.⁶ Such similarity strongly supports the notion that, from an electrophysiological perspective, chronic migraine can be conceptualized as a 'never-ending migraine attack'.³⁸ 8

9 In addition, results from our study show that the negative correlation between this lowfrequency-to-gamma (feedback/feedforward) activity ratio and the number of all headache 10 11 days was stronger than that of specific migraine days. The pathophysiological distinction 12 between archetypal migraine attacks and episodes of mild headache that co-occur in migraine 13 patients is to date a matter of debate. Indeed, previous pClinical studiesharmacological studies have shown that these mild headaches without migrainous features with a tension-type like 14 phenotype respond just like full-blown migraine attacks to specific anti-migraine drugs like 15 triptans.²⁶ Given that in oOur findings might suggest that most headaches in migraine 16 patients, with or without migrainous features, have a similar pathophysiological underpinning. 17 This hypothesis merits further studies study the total number of headache days exhibited the 18 strongest electrophysiological correlation with the (feedback/feedforward) activity ratio (and 19 not the number of migraine-specific days), one possible interpretation of our findings would 20 be that, in migraine patients, all recurrent headaches constitute manifestations of the same 21 pathophysiological phenomenon that present with different degrees of intensity. bBecause of 22 the its potential implications of this conjecture in the diagnosis of chronic migraine⁴⁹. we 23 24 consider that this hypothesis merits further study.

Interestingly, -thise feedback/feedforward ratio was remarkably similar between ictal episodic
and chronic migraine patients. Such similarity was also reported for other electrophysiological
features and chronic migraineurs; a resemblance that has been described for other
electrophysiological features in the past -⁶ and confirms thatSuch similarity strongly supports
the notion that, from an electrophysiological perspective, chronic migraine can be
conceptualized asresembles a 'never-ending migraine attack' as far as cortical
electrophysiology is concerned.³⁸

This-Our experiment study has some several limitations worth to mention. Analysis of gamma 1 band activity does not allow notch filtering utilisation at the frequency of the power line (AC) 2 and one cannot exclude that the gamma band power was to therefore, despite our biggest 3 efforts, some degree of contaminated by the power line oscillations. However, as mentioned, 4 5 gamma activity exhibited temporal fluctuations in our study, which would be expected from a neural signal, and was not constant over time, as would be 50Hz power line noise. 6 7 contamination of the signal is probable. Also, artefact rejection with single channel recordings is restricted, and because of that, hence subtraction of muscular muscle activity^{29,47} or 8 miniature ocular saccades⁴⁸ was not possible. Moreover, the two standard deviations from the 9 channel mean amplitude limit that we employed for artefact rejection was empirically chosen 10 and, although apparently adequate, needs to be experimentally corroborated. FurthermoreOf 11 12 note, since our analysis was limited to a single derivation (Oz), it and therefore lacks spatial 13 resolution. Multi-channel recordings using high-density EEG would allow to perform a spatial decomposition which would permit an anatomical segregation of neural activity and much 14 15 better artefact suppression. Analysing pre-stimulus spectral power, and the influence of different temporal frequencies of the visual stimulus would also be worthwhile. Likewise, 16 17 although signal analyses were automated, blinding the investigators would have been 18 advantageous. With regards to methodologic issues subjects, different patients were included in the ictal and interictal episodic migraine groups. In future studies, it would be preferable to 19 compare the same patients in and outside of an attack, which would allow a more powerful 20 paired analysis. For some episodic migraine patients, the next attack following the VEP 21 recordings occurred after the 30-day headache diary registry had ended and thus we were 22 unable to correlate their electrophysiological results with time elapsed before/after the most 23 proximal attack. AdditionallyGgiven that our sample of migraine patients was entirely 24 comprised by composed of migraine patients without aura patients, our the results cannot be 25 readily extrapolated to migraine with aura patients before further testing. Pphotophobia was 26 27 not quantitatively assessed, which impeded us from correlating this clinical symptom with 28 electrophysiological data. Finally, in the future it would be of interest to explore the dynamic, (intra-individual) fluctuations of the low -frequency-to-gamma ratio over the migraine cycle, 29 and its correlation with PR-VEP habituation, the most common neurophysiological 30 abnormality in migraine. 31

- 32
- 33

References:

2	1.	Áfra J, Proietti Cecchini A, Sándor PS, Schoenen J: Comparison of visual and auditory
3		evoked cortical potentials in migraine patients between attacks. Clin Neurophysiol
4		[Internet] 111:1124–9, 2000. Available from:
5		http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Cit
6		ation&list_uids=10825720
7	2.	Ambrosini A, Coppola G, Gérardy PY, Pierelli F, Schoenen J: Intensity dependence of
8		auditory evoked potentials during light interference in migraine. Neurosci Lett 492:80-
9		3, 2011.
10	3.	Boulloche N, Denuelle M, Payoux P, Fabre N, Trotter Y, Géraud G: Photophobia in
11		migraine: An interictal PET study of cortical hyperexcitability and its modulation by
12		pain. J Neurol Neurosurg Psychiatry 81:978-84, 2010.
13	4.	Chang PF, Arendt-Nielsen L, Chen ACN: Dynamic changes and spatial correlation of
14		EEG activities during cold pressor test in man. Brain Res Bull [Internet] 57:667–75,
15		2002 [cited 2018 Jul 31]. Available from:
16		http://www.ncbi.nlm.nih.gov/pubmed/11927371
17	5.	Chang PF, Arendt-Nielsen L, Graven-Nielsen T, Svensson P, Chen AC: Topographic
18		effects of tonic cutaneous nociceptive stimulation on human electroencephalograph.
19		Neurosci Lett [Internet] 305:49-52, 2001 [cited 2018 Jul 31]. Available from:
20		http://www.ncbi.nlm.nih.gov/pubmed/11356305
21	6.	Chen WT, Wang SJ, Fuh JL, Lin CP, Ko YC, Lin YY: Persistent ictal-like visual
22		cortical excitability in chronic migraine. Pain [Internet] International Association for
23		the Study of Pain; 152:254–8, 2011. Available from:
24		http://dx.doi.org/10.1016/j.pain.2010.08.047
25	7.	Coppola G, Ambrosini a., Di Clemente L, Magis D, Fumal a., Gérard P, Pierelli F,

1		Schoenen J: Interictal abnormalities of gamma band activity in visual evoked responses
2		in migraine: an indication of thalamocortical dysrhythmia? Cephalalgia [Internet]
3		27:1360–7, 2007 [cited 2016 Apr 29]. Available from:
4		http://www.ncbi.nlm.nih.gov/pubmed/17986271
5	8.	Coppola G, Iacovelli E, Bracaglia M, Serrao M, Di Lorenzo C, Pierelli F:
6		Electrophysiological correlates of episodic migraine chronification: evidence for
7		thalamic involvement. J Headache Pain [Internet] 14:76, 2013. Available from:
8		http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3844625&tool=pmcentrez
9		&rendertype=abstract
10	9.	Coppola G, Di Lorenzo C, Schoenen J, Pierelli F: Habituation and sensitization in
11		primary headaches. J Headache Pain [Internet] 14:65, 2013. Available from:
12		http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3733593&tool=pmcentrez
13		&rendertype=abstract
14	10.	Coppola G, Parisi V, Di Lorenzo C, Serrao M, Magis D, Schoenen J, Pierelli F: Lateral
15		inhibition in visual cortex of migraine patients between attacks. J Headache Pain
16		[Internet] 14:20, 2013 [cited 2016 Feb 23]. Available from:
17		http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3620512&tool=pmcentrez
18		&rendertype=abstract
19	11.	Coppola G, Di Renzo A, Tinelli E, Di Lorenzo C, Di Lorenzo G, Parisi V, Serrao M,
20		Schoenen J, Pierelli F: Thalamo-cortical network activity during spontaneous migraine
21		attacks. Neurology [Internet] 87:2154-60, 2016 [cited 2018 Feb 5]. Available from:
22		http://www.ncbi.nlm.nih.gov/pubmed/27742813
23	12.	Coppola G, Vandenheede M, Di Clemente L, Ambrosini A, Fumal A, De Pasqua V,
24		Schoenen J: Somatosensory evoked high-frequency oscillations reflecting thalamo-
25		cortical activity are decreased in migraine patients between attacks. Brain [Internet]

1		128:98-103, 2005. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15563513
2	13.	Delorme A, Makeig S: EEGLAB: an open source toolbox for analysis of single-trial
3		EEG dynamics including independent component analysis. J Neurosci Methods
4		[Internet] 134:9–21, 2004 [cited 2017 Apr 26]. Available from:
5		http://www.ncbi.nlm.nih.gov/pubmed/15102499
6	14.	Engel AK, Fries P, Singer W: Dynamic predictions: Oscillations and synchrony in top-
7		down processing. Nat Rev Neurosci 2:704–16, 2001.
8	15.	Fries P: A mechanism for cognitive dynamics: Neuronal communication through
9		neuronal coherence. Trends Cogn. Sci. page 474-802005.
10	16.	Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S:
11		Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev
12		[Internet] 97:553–622, 2017 [cited 2017 Jun 1]. Available from:
13		http://www.ncbi.nlm.nih.gov/pubmed/28179394
14	17.	Gross J, Schnitzler A, Timmermann L, Ploner M: Gamma Oscillations in Human
15		Primary Somatosensory Cortex Reflect Pain Perception. Fries P, editor. PLoS Biol
16		[Internet] 5:e133, 2007 [cited 2018 Jul 31]. Available from:
17		http://dx.plos.org/10.1371/journal.pbio.0050133
18	18.	Hauck M, Lorenz J, Engel AK: Attention to painful stimulation enhances gamma-band
19		activity and synchronization in human sensorimotor cortex. J Neurosci [Internet]
20		Society for Neuroscience; 27:9270–7, 2007 [cited 2018 Jul 31]. Available from:
21		http://www.ncbi.nlm.nih.gov/pubmed/17728441
22	19.	Hauck M, Schröder S, Meyer-Hamme G, Lorenz J, Friedrichs S, Nolte G, Gerloff C,
23		Engel AK: Acupuncture analgesia involves modulation of pain-induced gamma
24		oscillations and cortical network connectivity. Sci Rep [Internet] Nature Publishing
25		Group; 7:16307, 2017 [cited 2018 Mar 28]. Available from:

- 1 http://www.nature.com/articles/s41598-017-13633-4 2 20. Headache Classification Committee of the International Headache Society (IHS): The International Classification of Headache Disorders, 3rd edition (beta version). 3 Cephalalgia [Internet] 53:137–46, 2013 [cited 2016 Jul 28]. Available from: 4 http://www.ncbi.nlm.nih.gov/pubmed/23771276 5 21. Herrmann CS, Munk MHJ, Engel AK: Cognitive functions of gamma-band activity: 6 7 Memory match and utilization. Trends Cogn. Sci. page 347–552004. 8 22. Jensen O, Bonnefond M, VanRullen R: An oscillatory mechanism for prioritizing salient unattended stimuli [Internet]. Trends Cogn. Sci. Elsevier Current Trends; page 9 10 200–52012 [cited 2017 Nov 24]. Available from: http://www.sciencedirect.com/science/article/pii/S1364661312000575 11 12 23. Judit A, Sándor PS, Schoenen J: Habituation of visual and intensity dependence of auditory evoked cortical potentials tends to normalize just before and during the 13 migraine attack. Cephalalgia [Internet] 20:714–9, 2000 [cited 2016 Sep 20]. Available 14 from: http://www.ncbi.nlm.nih.gov/pubmed/11167900 15 24. van Kerkoerle T, Self MW, Dagnino B, Gariel-Mathis M-A, Poort J, van der Togt C, 16 Roelfsema PR: Alpha and gamma oscillations characterize feedback and feedforward 17 18 processing in monkey visual cortex. Proc Natl Acad Sci U S A [Internet] National Academy of Sciences; 111:14332–41, 2014 [cited 2017 Nov 22]. Available from: 19
- 20 http://www.ncbi.nlm.nih.gov/pubmed/25205811
- 21 25. Lambert GA, Hoskin KL, Zagami AS: Cortico-NRM influences on trigeminal neuronal
 22 sensation. Cephalalgia 28:640–52, 2008.
- 23 26. Lipton R, Cady R, Stewart W, Wilks K, Hall C: Diagnostic lessons from the spectrum
- study. Headache J Head Face Pain [Internet] Wiley/Blackwell (10.1111); 43:423–423,
- 25 2003 [cited 2018 Apr 4]. Available from: http://doi.wiley.com/10.1046/j.1526-

4610.2003.03085_1.x

2	27.	Lisicki M, D'Ostilio K, Coppola G, de Noordhout AM, Parisi V, Schoenen J, Magis D:
3		Brain correlates of single trial visual evoked potentials in migraine: More than meets
4		the eye. Front Neurol [Internet] 9:, 2018. Available from:
5		https://www.frontiersin.org/article/10.3389/fneur.2018.00393/full
6	28.	Michalareas G, Vezoli J, van Pelt S, Schoffelen J-M, Kennedy H, Fries P: Alpha-Beta
7		and Gamma Rhythms Subserve Feedback and Feedforward Influences among Human
8		Visual Cortical Areas. Neuron [Internet] 89:384–97, 2016 [cited 2017 Nov 22].
9		Available from: http://www.ncbi.nlm.nih.gov/pubmed/26777277
10	29.	Muthukumaraswamy SD: High-frequency brain activity and muscle artifacts in
11		MEG/EEG: a review and recommendations. Front Hum Neurosci, 2013.
12	30.	Nir R-R, Sinai A, Moont R, Harari E, Yarnitsky D: Tonic pain and continuous EEG:
13		Prediction of subjective pain perception by alpha-1 power during stimulation and at
14		rest. Clin Neurophysiol [Internet] 123:605-12, 2012 [cited 2018 Jul 31]. Available
15		from: http://www.ncbi.nlm.nih.gov/pubmed/21889398
16	31.	Noseda R, Kainz V, Jakubowski M, Gooley JJ, Saper CB, Digre K, Burstein R: A
17		neural mechanism for exacerbation of headache by light. Nat Neurosci [Internet]
18		Nature Publishing Group; 13:239–45, 2010 [cited 2016 May 29]. Available from:
19		http://dx.doi.org/10.1038/nn.2475
20	32.	Peng W, Hu L, Zhang Z, Hu Y: Changes of spontaneous oscillatory activity to tonic
21		heat pain. Zuo X-N, editor. PLoS One [Internet] Public Library of Science; 9:e91052,
22		2014 [cited 2018 Mar 28]. Available from:
23		http://dx.plos.org/10.1371/journal.pone.0091052
24	33.	Pfurtscheller G, Lopes da Silva FH: Event-related EEG/MEG synchronization and
25		desynchronization: basic principles. Clin Neurophysiol [Internet] 110:1842–57, 1999

1		[cited 2018 Aug 1]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10576479
2	34.	Porcaro C, Di Lorenzo G, Seri S, Pierelli F, Tecchio F, Coppola G: Impaired brainstem
3		and thalamic high-frequency oscillatory EEG activity in migraine between attacks.
4		Cephalalgia 37:915–26, 2017.
5	35.	Sakuma K, Takeshima T, Ishizaki K, Nakashima K: Somatosensory evoked high-
6		frequency oscillations in migraine patients. Clin Neurophysiol [Internet] 115:1857-62,
7		2004 [cited 2017 Sep 15]. Available from: http://www.clinph-
8		journal.com/article/S1388-2457(04)00106-3/pdf
9	36.	Salinas E, Sejnowski TJ: Correlated neuronal activity and the flow of neural
10		information. Nat. Rev. Neurosci. page 539-502001.
11	37.	Sava SL, De Pasqua V, Magis D, Schoenen J: Effects of visual cortex activation on the
12		nociceptive blink reflex in healthy subjects. PLoS One 9:, 2014.
13	38.	Schoenen J: Is chronic migraine a never-ending migraine attack? Pain [Internet]
14		152:239–40, 2011 [cited 2016 Jan 24]. Available from:
15		http://www.ncbi.nlm.nih.gov/pubmed/21168270
16	39.	Schulte LH, May A: The migraine generator revisited: continuous scanning of the
17		migraine cycle over 30 days and three spontaneous attacks. Brain [Internet] 139:1987-
18		93, 2016 [cited 2016 Aug 9]. Available from:
19		http://www.ncbi.nlm.nih.gov/pubmed/27190019
20	40.	Siegel M, Donner TH, Oostenveld R, Fries P, Engel AK: High-frequency activity in
21		human visual cortex is modulated by visual motion strength. Cereb Cortex 17:732-41,
22		2007.
23	41.	Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T,
24		Grozinski-Wolff M, Yang R, Ma Y, Aycardi E: Fremanezumab for the Preventive
25		Treatment of Chronic Migraine. N Engl J Med [Internet] 377:2113-22, 2017. Available

from:

http://www.nejm.org/doi/10.1056/NEJMoa1709038%0Ahttp://www.ncbi.nlm.nih.gov/
 pubmed/29171818

4 42. Singer W, Gray C: Visual feature integration and the temporal correlation hypothesis.
5 Annu Rev Neurosci [Internet] 18:555–86, 1995. Available from:

- 6 http://www.ncbi.nlm.nih.gov/pubmed/7605074
- 43. Siniatchkin M, Reich A-L, Shepherd AJ, van Baalen A, Siebner HR, Stephani U: Periictal changes of cortical excitability in children suffering from migraine without aura.
 Pain 147:132–40, 2009.
- 44. Tallon-Baudry C, Bertrand O: Oscillatory gamma activity and its role in object
 representation. Trends Cogn Sci 3:151–62, 1999.
- 12 45. Tiemann L, Schulz E, Gross J, Ploner M: Gamma oscillations as a neuronal correlate of
 13 the attentional effects of pain. Pain 150:302–8, 2010.
- 14 46. De Tommaso M, Marinazzo D, Guido M, Libro G, Stramaglia S, Nitti L, Lattanzi G,
- 15 Angelini L, Pellicoro M: Visually evoked phase synchronization changes of alpha
- rhythm in migraine: Correlations with clinical features. Int J Psychophysiol 57:203–10,
 2005.
- 18 47. Whitham EM, Pope KJ, Fitzgibbon SP, Lewis T, Clark CR, Loveless S, Broberg M,
- 19 Wallace A, DeLosAngeles D, Lillie P, Hardy A, Fronsko R, Pulbrook A, Willoughby
- 20 JO: Scalp electrical recording during paralysis: Quantitative evidence that EEG
- frequencies above 20 Hz are contaminated by EMG. Clin Neurophysiol , 2007.
- 48. Yuval-Greenberg S, Tomer O, Keren AS, Nelken I, Deouell LY: Transient Induced
- 23 Gamma-Band Response in EEG as a Manifestation of Miniature Saccades. Neuron,
- 24 2008.
- 49. Headache Classification Committee of the International Headache Society (IHS) The

1	International Classification of Headache Disorders, 3rd edition. Cephalalgia [Internet]
2	SAGE PublicationsSage UK: London, England; 38:1–211, 2018 [cited 2018 Jan 27].
3	Available from: http://journals.sagepub.com/doi/10.1177/0333102417738202
4	
5	

1 Figure legends:

2

Fig 1. Power (µV²) in the various frequency bands (Hz). Median power (bold line) ± standard error
(shaded area) is depicted for each group. Healthy volunteers (HV-blue) showed the lowest mean
power at all frequencies. Episodic migraine patients (EM-orange) have the highest alpha power values,
while gamma power is greatest amongst chronic migraine patients (CM-red), followed by ictal
episodic migraine patients (IM-magenta).

Fig 2. Pattern-reversal visual evoked potential spectral analyses showing Alpha (left) and Gamma
(middle) area under the curve (x102µV2/Hz) and Alpha/Gamma area under the curve ratio (right) by
subject group. Asterisks (*) indicate significant differences between groups (p<0.05 corrected for
multiple comparisons). HV: healthy volunteers; EM: episodic migraine patients; CM: chronic
migraineurs; IM: episodic migraineurs during an attack.

Fig 3. Correlation between the visually induced alpha/gamma power ratio and the monthly number of
migraine days (left) or non-specific headache days (right). (*) p<0.05. Ictal migraine patients were not
included in this analysis.

Fig 4. Event related spectral perturbations in the gamma frequency range. Gamma activity is dynamically modulated throughout time. Areas delimited by a discontinuous line show the time and frequency range where gamma suppression reaches its maximum in healthy controls and episodic migraine patients in the inter-ictal period. See colour-scale on the right.

Fig 5. Schematic representation of feedback and feedforward signalling towards the primary visual cortex. Feedforward (green) signals reaching the primary visual cortex from the lateral geniculate nucleus induce oscillations in the gamma band frequency range. Feedback signals (red) originating in higher order visual areas (V2-V4) induce activity in the primary visual cortex within the alpha frequency band. Asterisks denote statistically significant differences. The box on the right shows how the distinct volleys reach different layers of the primary visual cortex.

Table 1. Participants' characteristics. Mean monthly migraine days and headache days did not differsignificantly between episodic migraine patients in the inter-ictal and ictal periods.

Table 2. Alpha and Gamma power $(x102\mu V2/Hz)$ and their ratio in the 4 subject groups: HV: healthy

volunteers (n=20); EM: interictal episodic migraineurs (n=30); CM: chronic migraineurs (n=20); IM:

30 ictal episodic migraineurs (n=20). Symbols: p<0.05 corrected for multiple comparisons, (*) as

31 compared to controls, (\dagger) as compared to interictal episodic migraine patients.

Headache related alterations of visual processing in migraine patients.

Marco Lisicki^{1†}, Kevin D'Ostilio^{1†}, Gianluca Coppola², Romain Nonis¹, Alain Maertens de Noordhout¹, Vincenzo Parisi², Delphine Magis^{1#}, Jean Schoenen^{1#}*.

¹ Headache Research Unit, CHR Citadelle Hospital, CHU de Liège. University of Liège Belgium.

² IRCCS - Fondazione Bietti, Research Unit of Neurophysiology of Vision and Neurophthalmology, Rome, Italy

[†]These authors equally participated in this study. [#]These authors contributed equally to the supervision of the study.

*Corresponding Author

Prof Jean Schoenen: University of Liège. University Department of Neurology, CHR Citadelle Hospital, Boulevard du 12eme de Ligne 1, 4000 Liege, Belgium. jschoenen@uliege.be, +32/4/225.63.83.

Running title:

Feedback & feedforward visual activity in migraine

Disclosures:

Funding

This project was part of the EUROHEADPAIN project - FP7 n° 602633 and received support from the Fonds d'Investissements de Recherche Scientifique (FIRS) of the CHU de Liège. GC was supported by the G.B. Bietti Foundation and the Italian Ministry of Health and Fondazione Roma.

Conflict of Interest

The authors of this study have no relevant conflict of interest to declare.

1 Abstract:

Migraine is characterized by an increased sensitivity to visual stimuli that worsens during
attacks. Recent evidence has shown that feedforward volleys carrying incoming visual
information induce high frequency (gamma) oscillations in the visual cortex, while feedback
volleys arriving from higher order brain areas induce oscillatory activity at lower frequencies
(theta/alpha/low-beta).

We investigated visually induced high (feedforward) and low (feedback) frequency activations in healthy subjects and various migraine patients. Visual evoked potentials from 20 healthy controls and 70 migraine patients (30 inter-ictal and 20 ictal episodic migraineurs, 20 chronic migraineurs) were analysed in the frequency domain. We compared power in the theta-alpha-low beta and gamma range between groups, and searched for correlations between the low-to-high frequency activity ratio and number of monthly headache and migraine days.

Compared to healthy controls, inter-ictal migraine patients had increased visually induced low 13 frequency (feedback) activity. Conversely, ictal and chronic migraine patients showed an 14 augmented (feedforward) gamma band power. The low-frequency-to-gamma 15 16 (feedback/feedforward) activity ratio correlated negatively with monthly headache days and tended to do so with migraine days. 17

Our findings show that visual processing is differentially altered depending on migraine cycle and type. Feedback control from higher order cortical areas predominates interictally in episodic migraine while migraine attacks and chronic migraine are associated with enhanced incoming afferent activity, confirming their similar electrophysiological profile. The presence of headache is associated with proportionally higher gamma (feedforward) activities.

1 **Perspective:**

This study provides an insight into the pathophysiology of migraine headache from the perspective of cortical sensory processing dynamics. Patients with migraine present alterations in feedback and feedforward visual signalling that differ with the presence of headache.

6 Keywords:

7 Visual evoked potentials, spectral analysis, episodic migraine, chronic migraine, feedback,8 feedforward.

1 Introduction

It is well established in healthy humans that marked changes in brain rhythmic oscillatory activity over a wide range of frequency bands are related to pain processing.^{30,32} This also applies for head pain associated to migraine. Several electrophysiological studies have shown that migraine is a brain disorder characterized by an abnormal cortico-subcortical oscillatory activity that fluctuates along the migraine cycle, differs between the ictal and inter-ictal intervals,^{7,12,34,35,46} and remains persistently altered as the disease chronifies.⁸

8 According to available experimental evidence, oscillations in the alpha and gamma frequency 9 bands can be used as direct, objective, experimentally stable, and interrelated measures of cognitive and sensory brain tasks. During on-going pain alpha power is reduced and gamma 10 power is increased in several brain regions,^{17,18,45} including posterior cortical areas.^{4,5} Similar 11 12 modifications correlate with active selection and integration of relevant unattended visual information, resulting from the balance between feedforward volleys reaching the visual 13 cortex from the lateral geniculate nucleus (fast gamma oscillations) and feedback activity 14 coming from higher order visual areas (low frequency (theta/alpha/low-beta) oscillations).^{24,28} 15 Spectral analysis allows to easily identify these two main frequency peaks (theta/alpha/low-16 beta and gamma) in common scalp-recorded visual evoked potentials (VEPs), as confirmed 17 recordings in 18 bv recent intracortical non-human primates as well as magnetoencephalographic studies in humans.^{24,28} 19

In this study we analysed the previously described fluctuations of visual processing in migraine^{23,39} from the perspective of visually induced feedback (theta/alpha/low-beta) and feedforward (gamma) activations. We also tested whether these alterations in visual signalling were specifically associated with the frequency of full-blown migraine attacks, or if they were also related to the presence of mild tension-type like headaches, often present in migraineurs, particularly in those suffering from chronic migraine.

26

27 Subjects and methods

28 Subjects

The study involved 90 participants: 20 healthy volunteers (HV), 30 episodic migraine without aura patients recorded during a headache-free interval (minimum 72 hours before or after an attack) verified on a headache diary and/or by a telephone call (EM), 20 ictal episodic

migraineurs recorded during an attack (IM, 17 during the headache phase, 3 within 48 hours 1 of the headache), and 20 chronic migraine patients without medication overuse (CM). 2 Diagnoses were made in accordance with The International Classification of Headache 3 Disorders 3rd edition beta version (ICHD3 beta).²⁰ Healthy volunteers did not report any first 4 degree relative suffering from recurrent headaches of any type. Participants were 5 consecutively recruited amongst University students or their families and via our headache 6 7 clinic. Specifically, an announcement was posted in the University's intra-net, and headache patients attending the consultation were personally invited to take part. Patients were not 8 9 under any preventive treatment, nor had they been for the 3 preceding months. To ascertain the diagnosis, attack occurrence, and headache attacks severity, patients filled in a paper diary 10 for \geq 30 days in which headache intensity, associated symptoms (nausea, vomiting, photo-, 11 phonophobia) and acute medication intake were registered. As in recent therapeutic trials,⁴¹ 12 13 only headaches fulfilling the diagnostic criteria for a migraine attack (ICHD3 beta code 1.1) (unless they had been treated with a triptan) were considered migraine specific headaches. All 14 15 other episodes of head pain were coded as unspecific headaches. None of the participants that initially agreed to participate were excluded afterwards. The study was approved by the 16 17 Hospital's ethics committee (Centre Hospitalier Régional de la Citadelle, Liège, Belgium protocol n°1422) and conducted following the principles of the Declaration of Helsinki. All 18 participants gave written informed consent. 19

20 Visual Evoked Potentials (VEP) recordings and analysis

VEP recordings were performed in the electrophysiology laboratory of the Headache 21 Research Unit (Neurology Department, Centre Hospitalier Régional de la Citadelle, Liège, 22 Belgium). All participants were studied in the morning, between 9 a.m. and noon. Subjects 23 24 were sitting on a comfortable armchair, in a quiet room with dimmed light. A patch was placed over the left eye, and needle recording electrodes were introduced in the scalp at Oz 25 26 (active) and Fz (reference) based on the 10-20 EEG system. During the recordings, subjects were instructed to maintain fixation on a red dot in the centre of a screen which displayed a 27 28 black and white reversing checkerboard pattern (contrast of 80%, mean luminance 50 cd/m2). Temporal and spatial stimulating frequencies employed were 1.55 Hz (3.1 reversals/second) 29 30 and 68' respectively. Six hundred epochs, each lasting 250ms, were continuously recorded at a sampling rate of 5.000 Hz using a CEDTM power 1401 device (Cambridge Electronic 31 Design Ltd, Cambridge, UK). After DC subtraction, recordings were exported to EEGLAB,¹³ 32 an open-source MATLAB (The MathWorks Inc.) toolbox for electrophysiological signal 33

processing, where they were band-pass filtered (low pass 100 Hz, high pass 1 Hz). Epochs 1 whose amplitude exceeded a two standard deviations from the channel mean amplitude limit 2 were considered artefacted and rejected (<6% of epochs). The Fast Fourier Transform was 3 applied on each epoch to compute spectral decomposition. Log-transform of single-trial 4 spectral power was performed before averaging. Data were zero-padded in order to increase 5 frequency resolution to steps of 1Hz. As in previous studies,²⁸ the two most prominent peaks 6 7 of the spectrogram were observed in the theta/alpha/low-beta (1) and gamma (2) frequency band ranges. To estimate power at these frequencies, the area under the curve (trapezoidal 8 9 numerical integration; MATLAB function 'trapz') of activity at each peak and nearby surrounding frequencies (4 to 16 Hz for theta-alpha-low beta and 40 to 60 Hz for gamma) was 10 calculated for each individual (Fig 1). Considering the recent evidence showing that alpha-11 beta and gamma activity embedded in visually-induced cortical responses convey different 12 information,^{24,28} and that abnormal visual responsiveness in migraine is the result of a 13 complex process involving several cortical areas,²⁷ we calculated the low frequency-to-14 15 gamma activity ratio as a measure of the interaction between simultaneous volleys reaching the visual cortex. In addition, considering the overlap between visually induced cerebral 16 17 gamma activity and the frequency spectrum of different possible sources of contamination of the signal (muscular artefacts, AC line noise) we performed a supplementary analysis of event 18 related spectral perturbations which permits to visually inspect changes in the power spectrum 19 throughout time. Investigators in this study were not blinded to diagnosis, but all 20 electrophysiological analyses were fully automated. 21

22 Statistical analysis

Statistical analyses and graphs were performed in Prism version 6.00 for Windows (GraphPad 23 24 Software, La Jolla, California, USA). The assumption of normal distribution was assessed using the Shapiro-Wilk normality test. Continuous variables were compared using ANOVA 25 26 or Kruskal-Wallis tests (in case of non-normal distributions or violations in the assumption of homoscedasticity evaluated using Bartlett's test), followed by post-hoc comparisons between 27 28 groups (corrected for multiple comparisons using Dunn's multiple comparison test). Correlation analyses between spectral power ratios and monthly number of headache or 29 30 migraine days were performed using Spearman's rank correlation test corrected for multiple comparisons by applying a Bonferroni correction. Because alterations in the power spectrum 31 of patients from the ictal migraine group are likely to be transient,^{1,39} these patients were not 32 included in correlation analyses. The significance level for all tests was set at p<0.05. 33

1 **Results**

2 There were no significant between-group differences in mean age or gender ratio in the whole

3 subject sample, nor between disease duration amongst migraine sub-groups (Table 1).

The results of spectral analyses are displayed in table 2. Mean low-frequency (theta-alpha-low 4 beta) power was significantly higher in headache-free episodic migraine patients compared to 5 healthy controls (Kruskal-Wallis test H= 8.330, p=0.040; Dunn's multiple comparisons test 6 7 (episodic migraine patients vs healthy controls) p = 0.030, adjusted for multiple comparisons). Conversely, gamma power was higher in both ictal and chronic migraine patients (Kruskal-8 9 Wallis test H= 14.00, p < 0.003; Dunn's multiple comparisons tests: chronic migraine vs healthy controls, p = 0.023; ictal migraine vs healthy controls, p = 0.013, both adjusted for 10 multiple comparisons) (Fig 1 & 2). The low-frequency-to-gamma activity ratio was 11 significantly smaller in ictal and chronic migraine patients compared to headache-free 12 episodic migraine patients, and in ictal migraine patients compared to healthy controls 13 (Kruskal-Wallis test H= 16.33, p= 0.001); Dunn's multiple comparisons tests: episodic vs 14 chronic, p = 0.032; episodic vs ictal, p = 0.012; healthy volunteers vs ictal, p = 0.024 (all 15 adjusted for multiple comparisons). A similar trend was observed between chronic migraine 16 patients and healthy controls, but it did not reach statistical significance (p=0.055) (Fig 2). 17 18 The low-frequency-to-gamma activity ratio was negatively correlated with the total number of 19 monthly headache days (ρ = -0.34; p= 0.015), but not with the total number of migraine specific days (ρ = -0.25; p=0.08) (Fig 3). A partial correlation (controlling for age) between 20 the low-frequency / gamma activity ratio and the monthly headache days was also significant 21 (r= -.33; p= 0.02). The N1-P1 amplitude of the broad-band VEP was not significantly 22 different between the groups (healthy controls: $5.088\mu V \pm 1,444$; headache free migraine 23 24 patients: 5.860 μ V ± 2.361; chronic migraine patients: 5.368 μ V ± 2.281; ictal migraine patients: 6.396 μ V ± 2.436; (one-way ANOVA F_(3.86) = 1.399; p=0.249). Supplementary 25 26 event-related spectral perturbations analysis (Fig 4) showed that gamma activity exhibited temporal fluctuations, as one would expect from a neural signal, rather than being constant 27 28 over time, as would be 50Hz power line noise or other possible sources of signal contamination. 29

30 **Discussion**

We measured power of low (theta/alpha/low-beta) and high (gamma) frequency oscillations embedded in pattern-reversal visual evoked potentials (PR-VEP) in healthy controls, episodic migraine patients during or in between attacks, and chronic migraineurs. The results show that, during headache, gamma power is greater in patients than in healthy subjects. By contrast, in the absence of headache, episodic migraine patients have increased low frequency power (theta/alpha/low-beta). Concordantly, the low-frequency-to-gamma activity ratio was significantly higher in headache-free patients than during a migraine attack or in chronic migraineurs and negatively correlated with the monthly number of headache days.

7 We have previously found a decreased habituation of late visual induced gamma components in headache-free interictal episodic migraine patients.⁷ In the present study we focused on 8 total gamma power and its relation with the low-frequency power spectrum analysed in the 9 frequency-domain, which is better suited to evaluate high frequency oscillations. There is 10 11 strong evidence showing that feedforward (afferent) volleys coming from the lateral geniculate nucleus induce oscillations within the gamma frequency range in the primary 12 13 visual cortex (Fig. 5). This frequency range has been associated with the efficiency of stimulus processing by thalamocortical networks ^{15,36,40} and with the translation of the 14 stimulus features into coherent perception (for a review, see Gray and Singer, 1995⁴²; 15 Tallon-Baudry and Bertrand, 1999⁴⁴). Therefore, increased visually induced gamma 16 (feedforward) activity during migraine attacks and in chronic migraine may reflect augmented 17 efficiency in the thalamo-cortical circuit. This is in line with previous 18 electrophysiological,^{8,9,23,43} and functional neuroimaging¹¹ studies showing that thalamo-19 cortical network activity is decreased in migraineurs during the headache-free interval, but 20 21 increased during an attack and with migraine chronification.

On the other hand, it is known that pain is accompanied by widespread enhancement of 22 gamma activity in the brain (prefrontal, mid-cingulate, and primary somatosensory cortices 23 and insula)¹⁹ associated with contralateral alpha power reductions,³² which suggests that the 24 former reflects tonic pain processing while the latter may be related to a top-down cognitive 25 process linked to attention.^{4,5,17,18,45} Reciprocal anatomical and functional connections 26 between the visual and the trigeminal systems are well documented in animals and human 27 beings.^{3,25,31,37} In particular, convergence of nociceptive trigeminal and visual afferents in the 28 posterior thalamus³⁰ may explain how head pain can amplify visually induced thalamocortical 29 30 activity, and thus gamma power in PR-VEP.

As opposed to feedforward afferent activity that generates gamma oscillations in the primary visual cortex, feedback volleys from higher order visual areas (V2-V4) induce oscillatory activity within the theta/alpha/low-beta frequency range (Fig. 5) that notably plays a role in

focusing attention to salient unattended stimuli.^{24,28} Such feedback volleys reaching the visual 1 cortex are able to modulate the response to visual afferents ^{14,21,23} by selectively inhibiting 2 high frequency (gamma) feedforward oscillations, and thus to exert a possible 'gating' 3 process.²² The sensory processing profile of migraine patients makes them vulnerable to 4 sensory overload,^{2,16} and therefore, in need of compensatory protective mechanisms. Between 5 attacks, repetitive photic stimulation causes whole-brain alpha hyper-synchronization,⁴⁶ 6 indicative of a diffuse cortical deactivation,³³ which may be favoured by the lower interictal 7 activity in thalamocortical networks.⁸ Our finding of increased theta/alpha/low-beta power 8 9 during the interictal phase of episodic migraine may thus reflect an increased feedback 10 inhibition restraining thalamo-cortical feedforward afferents as a protective (or compensatory) mechanism. Concordantly, short-range lateral inhibition in the visual cortex of episodic 11 migraineurs was found increased at the beginning of a sustained visual stimulation, but 12 decreased with subsequent persistent stimulus presentation.¹⁰ This phenomenon likely 13 contributes to the lack of habituation of broad-band PR-VEP, and supports the hypothesis that 14 15 the protective mechanism against sensory overload in migraine patients may at some point become overtaken. 16

17 The ratio between low frequency and gamma power was negatively correlated with disease activity, but more so with headache days than with qualified migraine days. Its lower value in 18 in chronic migraineurs could be due to the higher frequency of headache days in these 19 patients rendering them more likely to be recorded in close temporal relation to an attack. The 20 21 pathophysiological distinction between archetypal migraine attacks and episodes of mild headache that co-occur in migraine patients is a matter of debate. Clinical studies have shown 22 that these mild headaches with a tension-type like phenotype respond just like full-blown 23 migraine attacks to specific anti-migraine drugs like triptans.²⁶ Our findings might suggest 24 that most headaches in migraine patients, with or without migrainous features, have a similar 25 26 pathophysiological underpinning. This hypothesis merits further studies because of its potential implications in the diagnosis of chronic migraine⁴⁹. Interestingly, the 27 28 feedback/feedforward ratio was remarkably similar between ictal episodic and chronic migraine patients. Such similarity was also reported for other electrophysiological features ⁶ 29 and confirms that, chronic migraine resembles a 'never-ending migraine attack' as far as 30 cortical electrophysiology is concerned.³⁸ 31

Our study has several limitations. Analysis of gamma band activity does not allow notch filtering at the frequency of the power line (AC) and one cannot exclude that the gamma band

power was to some degree contaminated by the power line oscillations. However, as 1 mentioned, gamma activity exhibited temporal fluctuations in our study, which would be 2 expected from a neural signal, and was not constant over time, as would be 50Hz power line 3 noise. Also, artefact rejection with single channel recordings is restricted, and hence 4 subtraction of muscle activity^{29,47} or miniature ocular saccades⁴⁸ was not possible. Moreover, 5 the two standard deviations from the channel mean amplitude limit that we employed for 6 7 artefact rejection was empirically chosen and, although apparently adequate, needs to be experimentally corroborated. Of note, since our analysis was limited to a single derivation 8 9 (Oz), it lacks spatial resolution. Multi-channel recordings using high-density EEG would allow to perform anatomical segregation of neural activity and much better artefact 10 suppression. Analysing pre-stimulus spectral power, and the influence of different temporal 11 12 frequencies of the visual stimulus would also be worthwhile. Likewise, although signal 13 analyses were automated, blinding the investigators would have been advantageous. With regards to subjects, different patients were included in the ictal and interictal episodic 14 15 migraine groups. In future studies, it would be preferable to compare the same patients in and outside of an attack, which would allow a more powerful paired analysis. For some episodic 16 17 migraine patients, the next attack following the VEP recordings occurred after the 30-day headache diary registry had ended and thus we were unable to correlate their 18 electrophysiological results with time elapsed before/after the most proximal attack. Given 19 20 that our sample of migraine patients was entirely composed of migraine without aura patients, the results cannot be readily extrapolated to migraine with aura patients before further testing. 21 Photophobia was not quantitatively assessed, which impeded us from correlating this clinical 22 symptom with electrophysiological data. Finally, in the future it would be of interest to 23 explore the dynamic, intra-individual fluctuations of the low frequency-to-gamma ratio over 24 the migraine cycle, and its correlation with PR-VEP habituation, the most common 25 26 neurophysiological abnormality in migraine.

27

28

29 **References**:

Áfra J, Proietti Cecchini A, Sándor PS, Schoenen J: Comparison of visual and auditory
 evoked cortical potentials in migraine patients between attacks. Clin Neurophysiol
 [Internet] 111:1124–9, 2000. Available from:

1		http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Cit
2		ation&list_uids=10825720
3	2.	Ambrosini A, Coppola G, Gérardy PY, Pierelli F, Schoenen J: Intensity dependence of
4		auditory evoked potentials during light interference in migraine. Neurosci Lett 492:80-
5		3, 2011.
6	3.	Boulloche N, Denuelle M, Payoux P, Fabre N, Trotter Y, Géraud G: Photophobia in
7		migraine: An interictal PET study of cortical hyperexcitability and its modulation by
8		pain. J Neurol Neurosurg Psychiatry 81:978-84, 2010.
9	4.	Chang PF, Arendt-Nielsen L, Chen ACN: Dynamic changes and spatial correlation of
10		EEG activities during cold pressor test in man. Brain Res Bull [Internet] 57:667–75,
11		2002 [cited 2018 Jul 31]. Available from:
12		http://www.ncbi.nlm.nih.gov/pubmed/11927371
13	5.	Chang PF, Arendt-Nielsen L, Graven-Nielsen T, Svensson P, Chen AC: Topographic
14		effects of tonic cutaneous nociceptive stimulation on human electroencephalograph.
15		Neurosci Lett [Internet] 305:49-52, 2001 [cited 2018 Jul 31]. Available from:
16		http://www.ncbi.nlm.nih.gov/pubmed/11356305
17	6.	Chen WT, Wang SJ, Fuh JL, Lin CP, Ko YC, Lin YY: Persistent ictal-like visual
18		cortical excitability in chronic migraine. Pain [Internet] International Association for
19		the Study of Pain; 152:254–8, 2011. Available from:
20		http://dx.doi.org/10.1016/j.pain.2010.08.047
21	7.	Coppola G, Ambrosini a., Di Clemente L, Magis D, Fumal a., Gérard P, Pierelli F,
22		Schoenen J: Interictal abnormalities of gamma band activity in visual evoked responses
23		in migraine: an indication of thalamocortical dysrhythmia? Cephalalgia [Internet]
24		27:1360–7, 2007 [cited 2016 Apr 29]. Available from:
25		http://www.ncbi.nlm.nih.gov/pubmed/17986271

1	8.	Coppola G, Iacovelli E, Bracaglia M, Serrao M, Di Lorenzo C, Pierelli F:
2		Electrophysiological correlates of episodic migraine chronification: evidence for
3		thalamic involvement. J Headache Pain [Internet] 14:76, 2013. Available from:
4		http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3844625&tool=pmcentrez
5		&rendertype=abstract
6	9.	Coppola G, Di Lorenzo C, Schoenen J, Pierelli F: Habituation and sensitization in
7		primary headaches. J Headache Pain [Internet] 14:65, 2013. Available from:
8		http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3733593&tool=pmcentrez
9		&rendertype=abstract
10	10.	Coppola G, Parisi V, Di Lorenzo C, Serrao M, Magis D, Schoenen J, Pierelli F: Lateral
11		inhibition in visual cortex of migraine patients between attacks. J Headache Pain
12		[Internet] 14:20, 2013 [cited 2016 Feb 23]. Available from:
13		http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3620512&tool=pmcentrez
14		&rendertype=abstract
15	11.	Coppola G, Di Renzo A, Tinelli E, Di Lorenzo C, Di Lorenzo G, Parisi V, Serrao M,
16		Schoenen J, Pierelli F: Thalamo-cortical network activity during spontaneous migraine
17		attacks. Neurology [Internet] 87:2154-60, 2016 [cited 2018 Feb 5]. Available from:
18		http://www.ncbi.nlm.nih.gov/pubmed/27742813
19	12.	Coppola G, Vandenheede M, Di Clemente L, Ambrosini A, Fumal A, De Pasqua V,
20		Schoenen J: Somatosensory evoked high-frequency oscillations reflecting thalamo-
21		cortical activity are decreased in migraine patients between attacks. Brain [Internet]
22		128:98–103, 2005. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15563513
23	13.	Delorme A, Makeig S: EEGLAB: an open source toolbox for analysis of single-trial
24		EEG dynamics including independent component analysis. J Neurosci Methods
25		[Internet] 134:9–21, 2004 [cited 2017 Apr 26]. Available from:

- 1 http://www.ncbi.nlm.nih.gov/pubmed/15102499
- 2 14. Engel AK, Fries P, Singer W: Dynamic predictions: Oscillations and synchrony in top–
 down processing. Nat Rev Neurosci 2:704–16, 2001.
- 4 15. Fries P: A mechanism for cognitive dynamics: Neuronal communication through
 neuronal coherence. Trends Cogn. Sci. page 474–802005.
- 6 16. Goadsby PJ, Holland PR, Martins-Oliveira M, Hoffmann J, Schankin C, Akerman S:
- 7 Pathophysiology of Migraine: A Disorder of Sensory Processing. Physiol Rev

8 [Internet] 97:553–622, 2017 [cited 2017 Jun 1]. Available from:

- 9 http://www.ncbi.nlm.nih.gov/pubmed/28179394
- 10 17. Gross J, Schnitzler A, Timmermann L, Ploner M: Gamma Oscillations in Human
- 11 Primary Somatosensory Cortex Reflect Pain Perception. Fries P, editor. PLoS Biol

12 [Internet] 5:e133, 2007 [cited 2018 Jul 31]. Available from:

- 13 http://dx.plos.org/10.1371/journal.pbio.0050133
- 14 18. Hauck M, Lorenz J, Engel AK: Attention to painful stimulation enhances gamma-band
- 15 activity and synchronization in human sensorimotor cortex. J Neurosci [Internet]
- 16 Society for Neuroscience; 27:9270–7, 2007 [cited 2018 Jul 31]. Available from:

17 http://www.ncbi.nlm.nih.gov/pubmed/17728441

- 18 19. Hauck M, Schröder S, Meyer-Hamme G, Lorenz J, Friedrichs S, Nolte G, Gerloff C,
- 19 Engel AK: Acupuncture analgesia involves modulation of pain-induced gamma
- 20 oscillations and cortical network connectivity. Sci Rep [Internet] Nature Publishing
- 21 Group; 7:16307, 2017 [cited 2018 Mar 28]. Available from:
- 22 http://www.nature.com/articles/s41598-017-13633-4
- 23 20. Headache Classification Committee of the International Headache Society (IHS): The
- 24 International Classification of Headache Disorders, 3rd edition (beta version).
- 25 Cephalalgia [Internet] 53:137–46, 2013 [cited 2016 Jul 28]. Available from:

1 http://www.ncbi.nlm.nih.gov/pubmed/23771276 21. Herrmann CS, Munk MHJ, Engel AK: Cognitive functions of gamma-band activity: 2 Memory match and utilization. Trends Cogn. Sci. page 347–552004. 3 4 22. Jensen O, Bonnefond M, VanRullen R: An oscillatory mechanism for prioritizing salient unattended stimuli [Internet]. Trends Cogn. Sci. Elsevier Current Trends; page 5 200–52012 [cited 2017 Nov 24]. Available from: 6 7 http://www.sciencedirect.com/science/article/pii/S1364661312000575 8 23. Judit A, Sándor PS, Schoenen J: Habituation of visual and intensity dependence of auditory evoked cortical potentials tends to normalize just before and during the 9 10 migraine attack. Cephalalgia [Internet] 20:714–9, 2000 [cited 2016 Sep 20]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11167900 11 12 24. van Kerkoerle T, Self MW, Dagnino B, Gariel-Mathis M-A, Poort J, van der Togt C, Roelfsema PR: Alpha and gamma oscillations characterize feedback and feedforward 13 processing in monkey visual cortex. Proc Natl Acad Sci U S A [Internet] National 14 Academy of Sciences; 111:14332–41, 2014 [cited 2017 Nov 22]. Available from: 15 http://www.ncbi.nlm.nih.gov/pubmed/25205811 16 Lambert GA, Hoskin KL, Zagami AS: Cortico-NRM influences on trigeminal neuronal 17 25. 18 sensation. Cephalalgia 28:640-52, 2008. 26. Lipton R, Cady R, Stewart W, Wilks K, Hall C: Diagnostic lessons from the spectrum 19 study. Headache J Head Face Pain [Internet] Wiley/Blackwell (10.1111); 43:423-423, 20 2003 [cited 2018 Apr 4]. Available from: http://doi.wiley.com/10.1046/j.1526-21 22 4610.2003.03085_1.x 27. Lisicki M, D'Ostilio K, Coppola G, de Noordhout AM, Parisi V, Schoenen J, Magis D: 23 Brain correlates of single trial visual evoked potentials in migraine: More than meets 24 the eye. Front Neurol [Internet] 9:, 2018. Available from: 25

1		https://www.frontiersin.org/article/10.3389/fneur.2018.00393/full
2	28.	Michalareas G, Vezoli J, van Pelt S, Schoffelen J-M, Kennedy H, Fries P: Alpha-Beta
3		and Gamma Rhythms Subserve Feedback and Feedforward Influences among Human
4		Visual Cortical Areas. Neuron [Internet] 89:384–97, 2016 [cited 2017 Nov 22].
5		Available from: http://www.ncbi.nlm.nih.gov/pubmed/26777277
6	29.	Muthukumaraswamy SD: High-frequency brain activity and muscle artifacts in
7		MEG/EEG: a review and recommendations. Front Hum Neurosci, 2013.
8	30.	Nir R-R, Sinai A, Moont R, Harari E, Yarnitsky D: Tonic pain and continuous EEG:
9		Prediction of subjective pain perception by alpha-1 power during stimulation and at
10		rest. Clin Neurophysiol [Internet] 123:605-12, 2012 [cited 2018 Jul 31]. Available
11		from: http://www.ncbi.nlm.nih.gov/pubmed/21889398
12	31.	Noseda R, Kainz V, Jakubowski M, Gooley JJ, Saper CB, Digre K, Burstein R: A
13		neural mechanism for exacerbation of headache by light. Nat Neurosci [Internet]
14		Nature Publishing Group; 13:239–45, 2010 [cited 2016 May 29]. Available from:
15		http://dx.doi.org/10.1038/nn.2475
16	32.	Peng W, Hu L, Zhang Z, Hu Y: Changes of spontaneous oscillatory activity to tonic
17		heat pain. Zuo X-N, editor. PLoS One [Internet] Public Library of Science; 9:e91052,
18		2014 [cited 2018 Mar 28]. Available from:
19		http://dx.plos.org/10.1371/journal.pone.0091052
20	33.	Pfurtscheller G, Lopes da Silva FH: Event-related EEG/MEG synchronization and
21		desynchronization: basic principles. Clin Neurophysiol [Internet] 110:1842-57, 1999
22		[cited 2018 Aug 1]. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10576479
23	34.	Porcaro C, Di Lorenzo G, Seri S, Pierelli F, Tecchio F, Coppola G: Impaired brainstem
24		and thalamic high-frequency oscillatory EEG activity in migraine between attacks.
25		Cephalalgia 37:915–26, 2017.

1	35.	Sakuma K, Takeshima T, Ishizaki K, Nakashima K: Somatosensory evoked high-
2		frequency oscillations in migraine patients. Clin Neurophysiol [Internet] 115:1857-62,
3		2004 [cited 2017 Sep 15]. Available from: http://www.clinph-
4		journal.com/article/S1388-2457(04)00106-3/pdf
5	36.	Salinas E, Sejnowski TJ: Correlated neuronal activity and the flow of neural
6		information. Nat. Rev. Neurosci. page 539-502001.
7	37.	Sava SL, De Pasqua V, Magis D, Schoenen J: Effects of visual cortex activation on the
8		nociceptive blink reflex in healthy subjects. PLoS One 9:, 2014.
9	38.	Schoenen J: Is chronic migraine a never-ending migraine attack? Pain [Internet]
10		152:239–40, 2011 [cited 2016 Jan 24]. Available from:
11		http://www.ncbi.nlm.nih.gov/pubmed/21168270
12	39.	Schulte LH, May A: The migraine generator revisited: continuous scanning of the
13		migraine cycle over 30 days and three spontaneous attacks. Brain [Internet] 139:1987-
14		93, 2016 [cited 2016 Aug 9]. Available from:
15		http://www.ncbi.nlm.nih.gov/pubmed/27190019
16	40.	Siegel M, Donner TH, Oostenveld R, Fries P, Engel AK: High-frequency activity in
17		human visual cortex is modulated by visual motion strength. Cereb Cortex 17:732-41,
18		2007.
19	41.	Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T,
20		Grozinski-Wolff M, Yang R, Ma Y, Aycardi E: Fremanezumab for the Preventive
21		Treatment of Chronic Migraine. N Engl J Med [Internet] 377:2113–22, 2017. Available
22		from:
23		http://www.nejm.org/doi/10.1056/NEJMoa1709038%0Ahttp://www.ncbi.nlm.nih.gov/
24		pubmed/29171818
25	42.	Singer W, Gray C: Visual feature integration and the temporal correlation hypothesis.

1		Annu Rev Neurosci [Internet] 18:555–86, 1995. Available from:
2		http://www.ncbi.nlm.nih.gov/pubmed/7605074
3	43.	Siniatchkin M, Reich A-L, Shepherd AJ, van Baalen A, Siebner HR, Stephani U: Peri-
4		ictal changes of cortical excitability in children suffering from migraine without aura.
5		Pain 147:132–40, 2009.
6	44.	Tallon-Baudry C, Bertrand O: Oscillatory gamma activity and its role in object
7		representation. Trends Cogn Sci 3:151–62, 1999.
8	45.	Tiemann L, Schulz E, Gross J, Ploner M: Gamma oscillations as a neuronal correlate of
9		the attentional effects of pain. Pain 150:302-8, 2010.
10	46.	De Tommaso M, Marinazzo D, Guido M, Libro G, Stramaglia S, Nitti L, Lattanzi G,
11		Angelini L, Pellicoro M: Visually evoked phase synchronization changes of alpha
12		rhythm in migraine: Correlations with clinical features. Int J Psychophysiol 57:203–10,
13		2005.
14	47.	Whitham EM, Pope KJ, Fitzgibbon SP, Lewis T, Clark CR, Loveless S, Broberg M,
15		Wallace A, DeLosAngeles D, Lillie P, Hardy A, Fronsko R, Pulbrook A, Willoughby
16		JO: Scalp electrical recording during paralysis: Quantitative evidence that EEG
17		frequencies above 20 Hz are contaminated by EMG. Clin Neurophysiol, 2007.
18	48.	Yuval-Greenberg S, Tomer O, Keren AS, Nelken I, Deouell LY: Transient Induced
19		Gamma-Band Response in EEG as a Manifestation of Miniature Saccades. Neuron,
20		2008.
21	49.	Headache Classification Committee of the International Headache Society (IHS) The
22		International Classification of Headache Disorders, 3rd edition. Cephalalgia [Internet]
23		SAGE PublicationsSage UK: London, England; 38:1–211, 2018 [cited 2018 Jan 27].
24		Available from: http://journals.sagepub.com/doi/10.1177/0333102417738202
25		

1 Figure legends:

2

Fig 1. Power (µV²) in the various frequency bands (Hz). Median power (bold line) ± standard error
(shaded area) is depicted for each group. Healthy volunteers (HV-blue) showed the lowest mean
power at all frequencies. Episodic migraine patients (EM-orange) have the highest alpha power values,
while gamma power is greatest amongst chronic migraine patients (CM-red), followed by ictal
episodic migraine patients (IM-magenta).

Fig 2. Pattern-reversal visual evoked potential spectral analyses showing Alpha (left) and Gamma
(middle) area under the curve (x102µV2/Hz) and Alpha/Gamma area under the curve ratio (right) by
subject group. Asterisks (*) indicate significant differences between groups (p<0.05 corrected for
multiple comparisons). HV: healthy volunteers; EM: episodic migraine patients; CM: chronic
migraineurs; IM: episodic migraineurs during an attack.

Fig 3. Correlation between the visually induced alpha/gamma power ratio and the monthly number of
migraine days (left) or non-specific headache days (right). (*) p<0.05. Ictal migraine patients were not
included in this analysis.

Fig 4. Event related spectral perturbations in the gamma frequency range. Gamma activity is dynamically modulated throughout time. Areas delimited by a discontinuous line show the time and frequency range where gamma suppression reaches its maximum in healthy controls and episodic migraine patients in the inter-ictal period. See colour-scale on the right.

Fig 5. Schematic representation of feedback and feedforward signalling towards the primary visual cortex. Feedforward (green) signals reaching the primary visual cortex from the lateral geniculate nucleus induce oscillations in the gamma band frequency range. Feedback signals (red) originating in higher order visual areas (V2-V4) induce activity in the primary visual cortex within the alpha frequency band. Asterisks denote statistically significant differences.

Table 1. Participants' characteristics. Mean monthly migraine days and headache days did not differsignificantly between episodic migraine patients in the inter-ictal and ictal periods.

Table 2. Alpha and Gamma power ($x102\mu$ V2/Hz) and their ratio in the 4 subject groups: HV: healthy

volunteers (n=20); EM: interictal episodic migraineurs (n=30); CM: chronic migraineurs (n=20); IM:

- ictal episodic migraineurs (n=20). Symbols: p<0.05 corrected for multiple comparisons, (*) as
- 30 compared to controls, (\dagger) as compared to interictal episodic migraine patients.

Highlights

- Visually-induced feedback and feedforward signalling is altered in migraine
- Inter-ictal episodic migraine patients show increased feedback to the visual cortex
- Ictal episodic and chronic migraine patients show augmented feedforward activity
- Electrophysiologically, chronic migraineurs resemble ictal episodic migraine patients
- All headaches in migraine patients have a similar electrophysiological background



Hz



Figure 2















	Healthy v	Healthy volunteers Inter-ictal episodic migraine		Ictal episod	Ictal episodic migraine		Chronic migraine		
Age (mean ± SD)	36.1	11.4	33.3	11.9	32.7	9.1	40.3	12.7	p = 0.126
Female percentage	75%		90	90%		0%	95%		p = 0.051
Disease duration (mean ± SD)			14.6	9.4	15.7	11.8	18.75	11.8	p = 0,430
Monthly migraine days (mean ± SD)			5.5	3.5	5.9	3.6	15.8	6.4	p < 0,001
Monthly headache days (mean \pm SD)			7.3	4.1	8.6	6.6	23.9	5.7	P < 0,001

	HV		E	EM		CM		IM	
	mean	SD	mean	SD	mean	SD	mean	SD	
Low frequency	635,6	± 12,1	651,0*	± 27,5	643,4	± 27,4	638,7	± 21,0	
Gamma	881,9	± 62,7	901,9	± 53,4	976,6*	± 116,6	965,7*	± 91,2	
Ratio	0,72	± 0,05	0,72	± 0,04	0,67†	± 0,08	0,67*†	± 0,06	

STROBE Statement—checklist of items that should be included in reports of observational studies

	ltem		Page # where this item
	No.	Recommendation	is located:
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or the	
		abstract	
		(b) Provide in the abstract an informative and balanced summary of what was	2
		done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation being	3
		reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	3
Methods			
Study design	4	Present key elements of study design early in the paper	3-4
Setting	5	Describe the setting, locations, and relevant dates, including periods of	4
		recruitment, exposure, follow-up, and data collection	
Participants	6	(a) Cohort study—Give the eligibility criteria, and the sources and methods of	3-4
		selection of participants. Describe methods of follow-up	
		Case-control study—Give the eligibility criteria, and the sources and methods	
		of case ascertainment and control selection. Give the rationale for the choice	
		of cases and controls	
		Cross-sectional study—Give the eligibility criteria, and the sources and	
		methods of selection of participants	
		(b) Cohort study—For matched studies, give matching criteria and number of	
		exposed and unexposed	
		Case-control study—For matched studies, give matching criteria and the	

number of controls per case	
Clearly define all outcomes, exposures, predictors, potential confounders,	3-4
and effect modifiers. Give diagnostic criteria, if applicable	
For each variable of interest, give sources of data and details of methods of	4
assessment (measurement). Describe comparability of assessment methods	
if there is more than one group	
Describe any efforts to address potential sources of bias	4
Explain how the study size was arrived at	n/a
7 ;*)	number of controls per case 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable * For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group O Describe any efforts to address potential sources of bias 0 Explain how the study size was arrived at

Continued on next page

variables describe which groupings were chosen and why Statistical 12 (a) bescribe all statistical methods, including those used to control for 5 methods (b) Describe any methods used to examine subgroups and interactions n/a (c) Explain how missing data were addressed n/a (c) Cohort study—If applicable, explain how loss to follow-up was addressed n/a (c) Cohort study—If applicable, explain how matching of cases and controls 3-4 was addressed case-control study—If applicable, describe analytical methods taking account n/a of sampling strategy (g) Describe any sensitivity analyses n/a (g) Describe any sensitivity analyses n/a	Quantitative	11	Explain how quantitative variables were handled in the analyses. If applicable,	3-5	
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding 5 methods (b) Describe any methods used to examine subgroups and interactions n/a (c) Explain how missing data were addressed n/a (c) Explain how missing data were addressed n/a (c) Explain how missing data were addressed 3-4 Case-control study—If applicable, explain how tost to follow-up was addressed 3-4 Case-control study—If applicable, describe analytical methods taking account of sampling strategy (g) Describe any sensitivity analyses n/a Results (a) Report numbers of inlividuals at each stage of study—eg numbers potentially 3-4 (b) Give reasons for non-participation at each stage 4 - (c) Consider use of a flow diagram n/a - Descriptive 14* (a) Give characteristics of study participants (eg demographic, clinical, social) 3-4 Ottcome data 5 Cohort study—Report numbers of outcome events or summary measures over time - Colord study—Report numbers of outcome events or summary measures over time - - Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and, if applicab	variables		describe which groupings were chosen and why		
methods confounding n/a (b) Describe any methods used to examine subgroups and interactions n/a (c) Explain how missing data were addressed n/a (d) Cohort study—If applicable, explain how loss to follow-up was addressed 3-4 Case-control study—If applicable, explain how matching of cases and controls was addressed 3-4 Cross-sectional study—If applicable, describe analytical methods taking account n/a of sampling strategy n/a (e) Describe any sensitivity analyses n/a Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially 3-4 eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed 10 (b) Give reasons for non-participation at each stage 4 12 14 data (a) Give characteristics of study participants (eg demographic, clinical, social) 3-4 Outcome data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) 3-4 Outcome data 15* Cross-sectional study—Report numbers of outcome events or summary measures over 16 Toross-sectional study—Report numbers of outcome ev	Statistical	12	(a) Describe all statistical methods, including those used to control for	5	
(b) Describe any methods used to examine subgroups and interactions n/a (c) Explain how missing data were addressed n/a (c) Cohort study—If applicable, explain how loss to follow-up was addressed 3-4 (c) Explain how missing data were addressed 14 (c) Explain how missing data were addressed 14 (c) Explain how missing data were addressed 14 (g) Describe any sensitivity analyses n/a Results 14* (a) Report numbers of individuals at each stage of study—eg numbers potentially eigible, examined for eigibility, confirmed eigible, included in the study, completing follow-up, and analysed 14 (b) Consider use of a flow diagram n/a Descriptive 14* (a) Give characteristics of study participants (g demographic, clinical, social) 3-4 (b) Cohort study—Summarise follow-up time (eg, average and total amo	methods		confounding		
(c) Explain how missing data were addressed n/a (d) Cohort study—If applicable, explain how loss to follow-up was addressed 3-4 (d) Cohort study—If applicable, explain how matching of cases and controls			(b) Describe any methods used to examine subgroups and interactions	n/a	
(d) Cohort study—If applicable, explain how loss to follow-up was addressed 3-4 Case-control study—If applicable, explain how matching of cases and controls 3-4 was addressed Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy n/a (e) Describe any sensitivity analyses n/a Results			(c) Explain how missing data were addressed	n/a	
Additional study If applicable, explain how matching of cases and controls was addressed vas vas addressed vas addressed vas addressed vas vas addressed vas vas addressed vas vas addressed vas addressed vas vas addressed v			(d) Cohort study—If applicable, explain how loss to follow-up was addressed	3-4	
was addressed was addressed Cross-sectional study—If applicable, describe analytical methods taking account of sampling strategy n/a Results (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed 3-4 (b) Give reasons for non-participation at each stage 4 (c) Consider use of a flow diagram n/a Descriptive 14* (a) Give characteristics of study participants (eg demographic, clinical, social) 3-4 (b) Indicate number of participants with missing data for each variable of interest (c) Cohort study—Summarise follow-up time (eg, average and total amount) 3-4 Outcome data 15* Coso-sectional study—Report numbers of outcome events or summary measures over time Case-control study—Report numbers of outcome events or summary measures of exposure 6 Main results 16 Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included 5					
Cross-sectional studyIf applicable, describe analytical methods taking account of sampling strategy n/a Results n/a Participants 13* (a) Report numbers of individuals at each stage of studyeg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed 3-4 (b) Give reasons for non-participation at each stage 4			was addressed		
of sampling strategy n/a Results			Cross-sectional study—If applicable, describe analytical methods taking account		
(e) Describe any sensitivity analyses n/a Results			of sampling strategy		
Results 3-4 Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed 3-4 (b) Give reasons for non-participation at each stage 4 4 (c) Consider use of a flow diagram n/a 14* (a) Give characteristics of study participants (eg demographic, clinical, social) and information on exposures and potential confounders 3-4 (b) Indicate number of participants with missing data for each variable of interest 3-4 (c) Cohort study—Summarise follow-up time (eg, average and total amount) 3-4 Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time 3-4 Cose-control study—Report numbers of outcome events or summary measures over time Case-control study—Report numbers of outcome events or summary measures of exposure 6 Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included 6			(<u>e</u>) Describe any sensitivity analyses	n/a	
Participants 13* (a) Report numbers of individuals at each stage of study—eg numbers potentially eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed 3-4 (b) Give reasons for non-participation at each stage 4 (c) Consider use of a flow diagram n/a Descriptive 14* (a) Give characteristics of study participants (eg demographic, clinical, social) 3-4 data and information on exposures and potential confounders 3-4 (c) Cohort study—Summarise follow-up time (eg, average and total amount) 3-4 Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time 3-4 Case-control study—Report numbers of outcome events or summary measures over measures Case-control study—Report numbers of outcome events or summary measures 6 Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included 6	Results				
eligible, examined for eligibility, confirmed eligible, included in the study, completing follow-up, and analysed	Participants	13*	(a) Report numbers of individuals at each stage of study—eg numbers potentially	3-4	
completing follow-up, and analysed 4 (b) Give reasons for non-participation at each stage 4 (c) Consider use of a flow diagram n/a Descriptive 14* (a) Give characteristics of study participants (eg demographic, clinical, social) 3-4 data and information on exposures and potential confounders 3-4 (b) Indicate number of participants with missing data for each variable of interest 3-4 (c) Cohort study—Summarise follow-up time (eg, average and total amount) 3-4 Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time time time time Cross-sectional study—Report numbers in each exposure category, or summary 6 measures of exposure for sub oppoint outcome events or summary 6 Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and, if applicable, confounders were adjusted for and why they were included time			eligible, examined for eligibility, confirmed eligible, included in the study,		
(b) Give reasons for non-participation at each stage 4 (c) Consider use of a flow diagram n/a Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) 3-4 data and information on exposures and potential confounders 3-4 (b) Indicate number of participants with missing data for each variable of interest 3-4 (c) Cohort study—Summarise follow-up time (eg, average and total amount) 3-4 Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time Case-control study—Report numbers in each exposure category, or summary measures of exposure Cross-sectional study—Report numbers of outcome events or summary Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included Were included			completing follow-up, and analysed		
(c) Consider use of a flow diagram n/a Descriptive data 14* (a) Give characteristics of study participants (eg demographic, clinical, social) 3-4 data and information on exposures and potential confounders 3-4 (b) Indicate number of participants with missing data for each variable of interest 3-4 (c) Cohort study—Summarise follow-up time (eg, average and total amount) 3-4 Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time Case-control study—Report numbers in each exposure category, or summary measures of exposure Cross-sectional study—Report numbers of outcome events or summary Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and, their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included were included			(b) Give reasons for non-participation at each stage	4	
Descriptive 14* (a) Give characteristics of study participants (eg demographic, clinical, social) 3-4 data and information on exposures and potential confounders 3-4 (b) Indicate number of participants with missing data for each variable of interest 3-4 (c) Cohort study—Summarise follow-up time (eg, average and total amount) 3-4 Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time time 1000000000000000000000000000000000000			(c) Consider use of a flow diagram	n/a	
data and information on exposures and potential confounders 3-4 (b) Indicate number of participants with missing data for each variable of interest 3-4 (c) Cohort study—Summarise follow-up time (eg, average and total amount)	Descriptive	14*	(a) Give characteristics of study participants (eg demographic, clinical, social)	3-4	
(b) Indicate number of participants with missing data for each variable of interest 3-4 (c) Cohort study—Summarise follow-up time (eg, average and total amount) (c) Cohort study—Report numbers of outcome events or summary measures over 0utcome data 15* Cohort study—Report numbers of outcome events or summary measures over time Case-control study—Report numbers in each exposure category, or summary measures of exposure Cross-sectional study—Report numbers of outcome events or summary measures 6 Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	data		and information on exposures and potential confounders		
(c) Cohort study—Summarise follow-up time (eg, average and total amount) Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time Case-control study—Report numbers in each exposure category, or summary measures of exposure Cross-sectional study—Report numbers of outcome events or summary measures 6 Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included			(b) Indicate number of participants with missing data for each variable of interest	3-4	
Outcome data 15* Cohort study—Report numbers of outcome events or summary measures over time Case-control study—Report numbers in each exposure category, or summary measures of exposure Cross-sectional study—Report numbers of outcome events or summary measures 6 Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included			(c) Cohort study—Summarise follow-up time (eg, average and total amount)		
time Case-control study—Report numbers in each exposure category, or summary measures of exposure Cross-sectional study—Report numbers of outcome events or summary measures Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Outcome data	15*	Cohort study—Report numbers of outcome events or summary measures over		
Case-control study—Report numbers in each exposure category, or summary measures of exposure Cross-sectional study—Report numbers of outcome events or summary measures Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included			time		
measures of exposure Cross-sectional study—Report numbers of outcome events or summary 6 Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included			Case-control study—Report numbers in each exposure category, or summary		
Cross-sectional study—Report numbers of outcome events or summary 6 measures 6 Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included 6			measures of exposure		
measures Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included			Cross-sectional study—Report numbers of outcome events or summary	6	
Main results 16 (a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included			measures		
and their precision (eg, 95% confidence interval). Make clear which confounders were adjusted for and why they were included	Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted estimates		
were adjusted for and why they were included			and their precision (eg, 95% confidence interval). Make clear which confounders		
			were adjusted for and why they were included		

(b) Report category boundaries when continuous variables were categorized

(c) If relevant, consider translating estimates of relative risk into absolute risk for

a meaningful time period

Continued on next page

Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions, and sensitivity analyses	4-5
Discussion			
Key results	18	Summarise key results with reference to study objectives	6
Limitations	19	Discuss limitations of the study, taking into account sources of potential bias or	9
		imprecision. Discuss both direction and magnitude of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives, limitations,	7-9
		multiplicity of analyses, results from similar studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	7-9
Other informati	on		
Funding	22	Give the source of funding and the role of the funders for the present study and, if	1
		applicable, for the original study on which the present article is based	

SCAN SIGNED DOCUMENT AND UPLOAD WITH REVISION (or) EMAIL WITH NEW SUBMISSION TO JPAIN@JPAIN.US

ASSIGNED MANUSCRIPT NUMBER (if applicable):

A Signature Below Certifies Compliance With the Following Statements:

Copyright Transfer. In consideration of the acceptance of the above work for publication, I do hereby assign and transfer to The American Pain Society (APS) all rights, title, and interest in and to the copyright in the above titled work.* This includes preliminary display/posting of the abstract of the accepted article in electronic form before publication. If any changes in authorship (order, deletions, or additions) occur after the manuscript is submitted, agreement by all authors for such changes must be on file with the APS. An author's name may only be removed at his/her own request. (Note: material prepared by employees of the US government in the course of official duties cannot be copyrighted.)

* Copyright is retained by authors who choose Elsevier's open access option.

For commercial companies, authorized agent signatures are allowed for copyright transfer but authors must sign for authorship responsibilities.

Authorship Responsibilities. I attest:

1) the manuscript is not currently under consideration elsewhere and the research reported will not be submitted for publication elsewhere until a final decision has been made by The Journal of Pain; I also attest that it is not in press at another journal nor will it be submitted elsewhere if accepted by The Journal of Pain; and I acknowledge that posting of submitted material on a website is considered prior publication;

2) the manuscript is truthful original work without fabrication, fraud, or plagiarism;

3) I have made substantial intellectual contributions to the submitted work, which include: (a) substantial contribution to the conception, design, acquisition or analysis and interpretation of the materials, and (b) drafting of the article or revising it critically for intellectual content; and

4) I have read the complete manuscript and take responsibility for the content and completeness of the manuscript and understand that if the paper, or part of the paper, is found to be faulty or fraudulent, I share responsibility.

Conflict of Interest Disclosure. All funding sources supporting the work and all institutional or corporate affiliations of mine are acknowledged. Except as disclosed on a separate attachment, I certify that I have no commercial associations (e.g., consultancies, stock ownership, equity interests, patent-licensing arrangements) that might pose a conflict of interest in connection with the submitted article (letter attached).

□ Please check if this article was written as part of the official duties of an employee of the US Government. Institutional Review Board/Animal Care Committee Approval. The undersigned author(s) certify that my institution has approved the protocol for any investigation involving humans or animals and that all experimentation was conducted in conformity with ethical and human principles of research.

Signature from EACH author is required (Email signed forms as attachments. May use multiple forms.)

Print Name: Do STILIO KEVIN	Date: <u>12DEC2018</u>
Print Name:	Date:
Print Name:	Date:
Print Name:	_ Date:
Print Name:	Date:
Print Name:	Date:
Print Name:	Date:
	Print Name:

The Journal of Pain Editorial Office JPAIN@JPAIN.US PH: (319) 430-4118 Submission link / Guide for Authors:http://ees.elsevier.com/jpain/ http://www.jpain.org

SCAN SIGNED DOCUMENT AND UPLOAD WITH REVISION (or) EMAIL WITH NEW SUBMISSION TO JPAIN@JPAIN.US

ASSIGNED MANUSCRIPT NUMBER (if applicable):

A Signature Below Certifies Compliance With the Following Statements:

Copyright Transfer. In consideration of the acceptance of the above work for publication, I do hereby assign and transfer to The American Pain Society (APS) all rights, title, and interest in and to the copyright in the above titled work.* This includes preliminary display/posting of the abstract of the accepted article in electronic form before publication. If any changes in authorship (order, deletions, or additions) occur after the manuscript is submitted, agreement by all authors for such changes must be on file with the APS. An author's name may only be removed at his/her own request. (Note: material prepared by employees of the US government in the course of official duties cannot be copyrighted.)

* Copyright is retained by authors who choose Elsevier's open access option.

For commercial companies, authorized agent signatures are allowed for copyright transfer but authors must sign for authorship responsibilities.

Authorship Responsibilities. I attest:

1) the manuscript is not currently under consideration elsewhere and the research reported will not be submitted for publication elsewhere until a final decision has been made by The Journal of Pain; I also attest that it is not in press at another journal nor will it be submitted elsewhere if accepted by The Journal of Pain; and I acknowledge that posting of submitted material on a website is considered prior publication;

2) the manuscript is truthful original work without fabrication, fraud, or plagiarism;

3) I have made substantial intellectual contributions to the submitted work, which include: **(a)** substantial contribution to the conception, design, acquisition or analysis and interpretation of the materials, and **(b)** drafting of the article or revising it critically for intellectual content; and

4) I have read the complete manuscript and take responsibility for the content and completeness of the manuscript and understand that if the paper, or part of the paper, is found to be faulty or fraudulent, I share responsibility.

Conflict of Interest Disclosure. All funding sources supporting the work and all institutional or corporate affiliations of mine are acknowledged. Except as disclosed on a separate attachment, I certify that I have no commercial associations (e.g., consultancies, stock ownership, equity interests, patent-licensing arrangements) that might pose a conflict of interest in connection with the submitted article (letter attached).

□ Please check if this article was written as part of the official duties of an employee of the US Government. Institutional Review Board/Animal Care Committee Approval. The undersigned author(s) certify that my institution has approved the protocol for any investigation involving humans or animals and that all experimentation was conducted in conformity with ethical and human principles of research.

Signature from EACH author is required (Email signed forms as attachments. <u>May use multiple forms</u>.)

Signature (1)	Print Name: Gianluca Coppola	Date:December 11, 2018
Signature (2)	Print Name:	Date:
Signature (3)	Print Name:	Date:
Signature (4)	Print Name:	Date:
Signature (5)	Print Name:	Date:
Signature (6)	Print Name:	Date:
Signature (7)	Print Name:	Date:

The Journal of Pain Editorial Office JPAIN@JPAIN.US PH: (319) 430-4118 Submission link / Guide for Authors:http://ees.elsevier.com/jpain/

SCAN SIGNED DOCUMENT AND UPLOAD WITH REVISION (or) EMAIL WITH NEW SUBMISSION TO JPAIN@JPAIN.US

ASSIGNED MANUSCRIPT NUMBER (if applicable):

A Signature Below Certifies Compliance With the Following Statements:

Copyright Transfer. In consideration of the acceptance of the above work for publication, I do hereby assign and transfer to The American Pain Society (APS) all rights, title, and interest in and to the copyright in the above titled work.* This includes preliminary display/posting of the abstract of the accepted article in electronic form before publication. If any changes in authorship (order, deletions, or additions) occur after the manuscript is submitted, agreement by all authors for such changes must be on file with the APS. An author's name may only be removed at his/her own request. (Note: material prepared by employees of the US government in the course of official duties cannot be copyrighted.)

* Copyright is retained by authors who choose Elsevier's open access option.

For commercial companies, authorized agent signatures are allowed for copyright transfer but authors must sign for authorship responsibilities.

Authorship Responsibilities. I attest:

1) the manuscript is not currently under consideration elsewhere and the research reported will not be submitted for publication elsewhere until a final decision has been made by The Journal of Pain; I also attest that it is not in press at another journal nor will it be submitted elsewhere if accepted by The Journal of Pain; and I acknowledge that posting of submitted material on a website is considered prior publication;

2) the manuscript is truthful original work without fabrication, fraud, or plagiarism;

3) I have made substantial intellectual contributions to the submitted work, which include: (a) substantial contribution to the conception, design, acquisition or analysis and interpretation of the materials, and (b) drafting of the article or revising it critically for intellectual content; and

4) I have read the complete manuscript and take responsibility for the content and completeness of the manuscript and understand that if the paper, or part of the paper, is found to be faulty or fraudulent, I share responsibility.

Conflict of Interest Disclosure. All funding sources supporting the work and all institutional or corporate affiliations of mine are acknowledged. Except as disclosed on a separate attachment, I certify that I have no commercial associations (e.g., consultancies, stock ownership, equity interests, patent-licensing arrangements) that might pose a conflict of interest in connection with the submitted article (letter attached).

Please check if this article was written as part of the official duties of an employee of the US Government. Institutional Review Board/Animal Care Committee Approval. The undersigned author(s) certify that my institution has approved the protocol for any investigation involving humans or animals and that all experimentation was conducted in conformity with ethical and human principles of research.

Signature from EACH author is required (Email signed forms as attachments. May use multiple forms.)

Signature (1)	DI DEL DIMA MACIE NEUROLECHT HILL INFORMATION BERNEN IN DIST AZZABILI Generation III DISTABILI Generation III DISTABILI Generatio DISTABILI GENERATIONI III DISTABILI GENERATIONI II DISTABILI GEN	Print Name:	Jean SCHOE	ENEN	Date: I	December 10, 2018
Signature (2) Signature (3) Signature (4) Signature (5) Signature (6) Signature (7)	PMA A	Print Name: I Print Name: Print Name: Print Name: Print Name: Print Name:	Delphine MAG Roriniv MARRENS	GIS Moru] de Noerdhoed ALAIN	Date: Date: Date: Date: Date: Date: Date:	January 11, 2019 <u>January M. 20</u> 19 <u>30/1/2019</u>

SCAN SIGNED DOCUMENT AND UPLOAD WITH REVISION (or) EMAIL WITH NEW SUBMISSION TO JPAIN@JPAIN.US

ASSIGNED MANUSCRIPT NUMBER (if applicable):

A Signature Below Certifies Compliance With the Following Statements:

Copyright Transfer. In consideration of the acceptance of the above work for publication, I do hereby assign and transfer to The American Pain Society (APS) all rights, title, and interest in and to the copyright in the above titled work.* This includes preliminary display/posting of the abstract of the accepted article in electronic form before publication. If any changes in authorship (order, deletions, or additions) occur after the manuscript is submitted, agreement by all authors for such changes must be on file with the APS. An author's name may only be removed at his/her own request. (Note: material prepared by employees of the US government in the course of official duties cannot be copyrighted.)

* Copyright is retained by authors who choose Elsevier's open access option.

For commercial companies, authorized agent signatures are allowed for copyright transfer but authors must sign for authorship responsibilities.

Authorship Responsibilities. I attest:

1) the manuscript is not currently under consideration elsewhere and the research reported will not be submitted for publication elsewhere until a final decision has been made by The Journal of Pain; I also attest that it is not in press at another journal nor will it be submitted elsewhere if accepted by The Journal of Pain; and I acknowledge that posting of submitted material on a website is considered prior publication;

2) the manuscript is truthful original work without fabrication, fraud, or plagiarism;

3) I have made substantial intellectual contributions to the submitted work, which include: **(a)** substantial contribution to the conception, design, acquisition or analysis and interpretation of the materials, and **(b)** drafting of the article or revising it critically for intellectual content; and

4) I have read the complete manuscript and take responsibility for the content and completeness of the manuscript and understand that if the paper, or part of the paper, is found to be faulty or fraudulent, I share responsibility.

Conflict of Interest Disclosure. All funding sources supporting the work and all institutional or corporate affiliations of mine are acknowledged. Except as disclosed on a separate attachment, I certify that I have no commercial associations (e.g., consultancies, stock ownership, equity interests, patent-licensing arrangements) that might pose a conflict of interest in connection with the submitted article (letter attached).

□ Please check if this article was written as part of the official duties of an employee of the US Government. Institutional Review Board/Animal Care Committee Approval. The undersigned author(s) certify that my institution has approved the protocol for any investigation involving humans or animals and that all experimentation was conducted in conformity with ethical and human principles of research.

Signature from EACH author is required (Email signed forms as attachments. May use multiple forms.)

	V - P >		
Signature (1)	Vinchos Vorma Print Name:Vincenzo Parisi _	Date:2018/12/10	
Signature (2)	Print Name:	Date:	
Signature (3)	Print Name:	Date:	
Signature (4)	Print Name:	Date:	
Signature (5)	Print Name:	Date:	
Signature (6)	Print Name:	Date:	
Signature (7)	Print Name:	Date:	

The Journal of Pain Editorial Office JPAIN@JPAIN.US PH: (319) 430-4118

SCAN SIGNED DOCUMENT AND UPLOAD WITH REVISION (or) EMAIL WITH NEW SUBMISSION TO JPAIN@JPAIN.US

ASSIGNED MANUSCRIPT NUMBER (if applicable):

A Signature Below Certifies Compliance With the Following Statements:

Copyright Transfer. In consideration of the acceptance of the above work for publication, I do hereby assign and transfer to The American Pain Society (APS) all rights, title, and interest in and to the copyright in the above titled work.* This includes preliminary display/posting of the abstract of the accepted article in electronic form before publication. If any changes in authorship (order, deletions, or additions) occur after the manuscript is submitted, agreement by all authors for such changes must be on file with the APS. An author's name may only be removed at his/her own request. (Note: material prepared by employees of the US government in the course of official duties cannot be copyrighted.)

* Copyright is retained by authors who choose Elsevier's open access option.

For commercial companies, authorized agent signatures are allowed for copyright transfer but authors must sign for authorship responsibilities.

Authorship Responsibilities. I attest:

1) the manuscript is not currently under consideration elsewhere and the research reported will not be submitted for publication elsewhere until a final decision has been made by The Journal of Pain; I also attest that it is not in press at another journal nor will it be submitted elsewhere if accepted by The Journal of Pain; and I acknowledge that posting of submitted material on a website is considered prior publication;

2) the manuscript is truthful original work without fabrication, fraud, or plagiarism;

3) I have made substantial intellectual contributions to the submitted work, which include: **(a)** substantial contribution to the conception, design, acquisition or analysis and interpretation of the materials, and **(b)** drafting of the article or revising it critically for intellectual content; and

4) I have read the complete manuscript and take responsibility for the content and completeness of the manuscript and understand that if the paper, or part of the paper, is found to be faulty or fraudulent, I share responsibility.

Conflict of Interest Disclosure. All funding sources supporting the work and all institutional or corporate affiliations of mine are acknowledged. Except as disclosed on a separate attachment, I certify that I have no commercial associations (e.g., consultancies, stock ownership, equity interests, patent-licensing arrangements) that might pose a conflict of interest in connection with the submitted article (letter attached).

□ Please check if this article was written as part of the official duties of an employee of the US Government. Institutional Review Board/Animal Care Committee Approval. The undersigned author(s) certify that my institution has approved the protocol for any investigation involving humans or animals and that all experimentation was conducted in conformity with ethical and human principles of research.

Signature from EACH author is required (Email signed forms as attachments. May use multiple forms.)

Print Name: Marco Lisicki Date: 5/2/2019 Signature (1) The Journal of Pain Editorial Office JPAIN@JPAIN.US PH: (319) 430-4118 Submission link / Guide for Authors:http://ees.elsevier.com/jpain/ http://www.jpain.org